{
    "info": {
        "nct_id": "NCT04046445",
        "official_title": "An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety, Tolerability, and Anti-Tumor Activity of ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer",
        "inclusion_criteria": "Cohort 1a\n\n1. Ability to comprehend and willingness to provide written informed consent (ICF) for the study.\n2. Age ≥ 18 years.\n3. Patient with histologically or cytologically confirmed stage IV CRC who has failed standard therapies.\n4. Must have received Standard of Care systemic treatment consisting of fluoropyrimidin- oxaliplatin and/or irinotecan based therapy for stage IV CRC disease.\n5. Presence of at least 1 measurable lesion by computed tomography or magnetic resonance imaging per RECIST v1.1 as determined by the local site investigator/radiologist assessment.\n6. Presence of at least one liver lesion amenable to repeated biopsy, ideally not the one being used for measuring.\n7. Willingness to undergo two fresh liver biopsies (pre-treatment and on-treatment).\n8. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.\n9. Life expectancy of at least 3 months.\n10. Resolution of all toxicities and any toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia). Patients with ≤ Grade 2 neuropathy and Grade ≤ 2 fatigue are an exception and may enroll.\n11. Adequate renal, hepatic, and hematologic functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.\n12. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L.\n13. Absolute lymphocyte count ≥ 0.5 × 109/L.\n14. Platelets ≥ 100 × 109/L.\n15. Hemoglobin level ≥ 9 g/dL.\n16. Measured or calculated creatinine clearance (glomerular filtration rate can also be used in place of creatinine clearance) ≥ 50 mL/min according to the formula of Cockcroft-Gault.\n17. Total bilirubin ≤ 1.5 × upper limit of normal (ULN); if total bilirubin is > 1.5 x ULN then direct bilirubin must be ≤ 1.5 × ULN. Patients with known Gilbert's Syndrome may enroll if total bilirubin ≤ 3 × ULN.\n18. Alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 2.5 × ULN or ≤ 5 x ULN in patients with hepatic involvement.\n19. A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n    Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to use highly effective contraceptive methods during the treatment period and for at least 180 days after the last dose of study treatment and refrain from egg donation during this period.\n20. A male patient must agree to use a contraceptive during the treatment period and for at least 180 days after the last dose of study treatment and refrain from donating sperm during this period.\n\nCohorts 1b, 2a, 2c, 3 and 4a:\n\n1. Ability to comprehend and willingness to provide written informed consent (ICF) for the study.\n2. Age ≥ 18 years.\n3. Histologically or cytologically confirmed CRC and MSS/MMR proficient status confirmed by polymerase chain reaction (PCR)/ immunohistochemistry or next generation sequencing (NGS) assay at local institution.\n4. Must have received a first line of SoC systemic therapy (physician choice) for stage IV disease and completed the therapy. They must have an ongoing partial response (PR) or a stable disease (SD) at the completion of this therapy, completion of therapy as defined by the investigator, however, with a minimum number of 4 months.\n\n   Note: Patient may have also received prior adjuvant therapy for stage II or III colorectal cancer, however the adjuvant treatment for stage II and III will not be considered as a prior line of therapy in case of relapse more than 6 months after the end of treatment.\n5. Presence of at least 1 measurable lesion by computed tomography or magnetic resonance imaging per RECIST v1.1 as determined by the local site investigator/radiologist assessment.\n6. Presence of at least one metastatic lesion amenable to paired biopsies (same lesion to be biopsied twice, at baseline and on D36), ideally not the one being used for measuring. However, liver lesions must be prioritized. Non-liver metastatic lesion biopsies may be collected only if the patient has no liver lesion or if the liver lesion is not amenable to paired biopsies (e.g. due to its size or location) or if the liver biopsy represents a risk or an undue inconvenience for the patient health/condition per Investigator judgment. In such cases, where a patient has no lesion amenable to biopsy at all, the paired biopsies may be waived by the Sponsor on a case-by-case basis.\n7. Willingness to undergo two biopsies (liver lesion must be prioritized). If the Investigator judges the biopsies to be a risk or an undue inconvenience for the patient health/condition, they may be waived by the Sponsor on a case-by-case basis.\n8. ECOG performance status 0 to 2.\n9. Life expectancy of at least 6 months.\n10. Has resolution of all toxicities and any toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia). Patients with ≤ Grade 2 neuropathy and Grade ≤ 2 fatigue are an exception and may enroll.\n11. Adequate renal, hepatic, thyroid and hematologic functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.\n12. Absolute neutrophil count ≥ 1.5 × 109/L.\n13. Absolute lymphocyte count ≥ 0.5 × 109/L.\n14. Platelets ≥ 100 × 109/L.\n15. Hemoglobin level ≥ 9 g/dL.\n16. Measured or calculated creatinine clearance (glomerular filtration rate can also be used in place of creatinine clearance) ≥ 50 mL/min according to the formula of Cockcroft-Gault (see Appendix 6).\n17. Total bilirubin ≤ 1.5 × ULN; if total bilirubin is > 1.5 x ULN then direct bilirubin must be ≤ 1.5 × ULN. Patients with known Gilbert's Syndrome may enroll if total bilirubin ≤ 3 × ULN.\n18. ALT/AST ≤ 2.5 × ULN or ≤ 5 × ULN in patients with hepatic involvement.\n19. A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n    Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to use highly effective contraceptive methods during the treatment period and for at least 180 days after the last dose of study treatment and refrain from egg donation during this period.\n20. A male patient must agree to use a contraceptive during the treatment period and for at least 180 days after the last dose of study treatment and refrain from donating sperm during this period.\n\nSpecific to Cohorts 3, 4a, 4b:\n\n1. Patient agrees to follow the instructions and precautions (see Section 4.4.1) related to potential VSV-GP128 shedding.\n\nCohorts 2b and 4b:\n\n1. Ability to comprehend and willingness to provide written informed consent (ICF) for the study.\n2. Age ≥ 18 years.\n3. Histologically or cytologically confirmed CRC and MSS/MMR proficient status confirmed by PCR/immunohistochemistry or NGS assay at local institution.\n4. Radiological evidence (CT/MRI) of liver-limited stage IV CRC.\n5. Must have received first line neoadjuvant SoC systemic therapy (physician choice) for stage IV disease. May have received up to 16 weeks of this systemic SoC therapy.\n\n   Note: Patient may have also received prior adjuvant therapy for stage II or III colorectal cancer, however the adjuvant treatment for stage II and III will not be considered as a prior line of therapy in case of relapse more than 6 months after the end of treatment.\n6. Absence of disease progression following neoadjuvant chemotherapy.\n7. Eligible for R0 complete liver metastasectomy (in case the primary tumor was already removed) or for R0 complete simultaneous combined resection (resection of both liver metastases and primary tumor in case the primary tumor is still in place) with curative intent.\n8. ECOG performance status 0 to 2.\n9. Life expectancy of at least 12 months.\n10. Adequate renal, hepatic, thyroid and hematologic functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.\n11. Absolute neutrophil count ≥ 1.5 × 109 /L.\n12. Absolute lymphocyte count ≥ 0.5 × 109 /L.\n13. Platelets ≥ 100 × 109/L.\n14. Hemoglobin level ≥ 9 g/dL.\n15. Measured or calculated creatinine clearance (glomerular filtration rate can also be used in place of creatinine clearance) ≥ 50 mL/min according to the formula of Cockcroft-Gault (see Appendix 6).\n16. Total bilirubin ≤ 1.5 × ULN; if total bilirubin is > 1.5 x ULN then direct bilirubin must be ≤ 1.5 × ULN. Patients with known Gilbert's Syndrome may enroll if total bilirubin ≤ 3 × ULN.\n17. ALT/AST ≤ 2.5 × ULN or ≤ 5 × ULN in patients with hepatic involvement.\n18. A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:\n\n    Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to use highly effective contraceptive methods during the treatment period and for at least 180 days after the last dose of study treatment and refrain from egg donation during this period.\n19. A male patient must agree to use a contraceptive during the treatment period and for at least 180 days after the last dose of study treatment and refrain from donating sperm during this period.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "All Cohorts:\n\n1. Unwilling or unable to follow protocol requirements or to give informed consent.\n2. Gastro-intestinal bowel obstruction (partial or complete).\n3. Participation in any other study with an investigational study drug or device requires Medical Monitor approval.\n4. Prior monoclonal antibody within 4 weeks or 5 half-lives (whichever is shorter) before administration of study treatment with the exception of bevacizumab (Avastin®), cetuximab (Erbitux®) and panitumumab (Vectibix®) which may have been received within 15 days from initiation of study treatment. Supportive care (e.g. denosumab) may be used before and during study treatment.\n5. Prior therapy with checkpoint inhibitors (anti-programmed death 1 (anti-PD-1), anti-programmed death-ligand 1 (anti-PD-L1), anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4)). Patients must not have received any investigational immunotherapy neither.\n6. Prior chemotherapy or targeted small molecule therapy within 15 days from initiation of study treatment.\n7. Prior radiotherapy within 2 weeks of enrolment or within 4 weeks of enrolment in the case of radiation to central nervous system (CNS), which requires ≥ 4-week washout. Patients must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.\n8. Major (according the Investigator's judgment) surgery within 12 weeks before enrolment.\n9. Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry with the exception of cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, ductal or lobular carcinoma in situ of the breast, or other non-invasive or indolent malignancy, or cancers from which the patient has been disease-free for > 1 year, after treatment with curative intent.\n10. Immunosuppression including the continued use of systemic (at prednisone dose equivalent of > 10 mg) or topical steroids at or near the injection site (excluding inhaled and eye drop-containing corticosteroids) or the use of immunosuppressive agents for any concurrent condition. All other corticosteroids must be discontinued > 4 weeks prior to first study treatment administration.\n11. Previous vaccination (either therapeutic and/or prophylactic) against mCRC.\n12. Pregnant/nursing women or unwilling to comply with acceptable contraceptive methods during study course.\n13. History of autoimmune disease including any active autoimmune disease except vitiligo or childhood asthma.\n14. Dermatological disease requiring local immunosuppressive agent.\n15. Chronic or concurrent active infectious disease requiring systemic antibodies, antifungal, or antiviral treatment.\n16. Known medical history of human immunodeficiency virus (HIV) infection or known medical history of acquired immunodeficiency syndrome (AIDS). HIV testing is not required unless mandated by the local health authority.\n17. Has known history of or is positive for hepatitis B (hepatitis B virus surface antigen [HBsAg] reactive) or hepatitis C (HCV RNA).\n\n    Note: Testing must be performed to determine eligibility. - Hepatitis B virus DNA must be undetectable and HBsAg negative at screening visit.- Hepatitis C antibody testing is allowed for screening purposes in countries where HCV RNA is not part of standard of care. In these cases, HCV antibody positive patients will be excluded.- Patients who have had definitive treatment for HCV are permitted if HCV RNA is undetectable at screening visit.\n18. Known active CNS metastasis and/or carcinomatous meningitis.\n19. Known cerebral oedema.\n20. Live vaccine received within 30 days before initiation of study treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed. however, intranasal influenza vaccines (FluMist®) are live attenuated vaccines and are not allowed. COVID-19 vaccines that are not live vaccines are allowed before and during study treatment. However, a COVID-19 vaccination should not occur within ± 2 days of ATP128 study drug and ± 15 days of VSV-GP128 study drug.\n21. History of allergy or hypersensitivity to any of the study drugs or study drug components.\n22. Any condition in the judgment of the Investigator which makes the patient unsuitable for trial participation.\n\n    Cohorts 1b, 2a, 2b, 2c, 3, 4a and 4b:\n23. Has received more than 1 line of therapy for stage IV disease (neoadjuvant therapy in Cohort 2b counts as 1 line).\n24. History of pneumonitis within the last 5 years.\n25. Active interstitial lung disease (ILD)/pneumonitis or a history of ILD/pneumonitis requiring treatment with systemic steroids and/or whose pulse oximetry is less than 92% \"on room air\".\n26. Any of the following cardiac criteria:\n\n    * Mean resting corrected QT interval (QTc) > 470 msec.\n    * Any clinically important abnormalities (as assessed by the Investigator) in rhythm, conduction, or morphology of resting ECGs, e.g., complete left bundle branch block, third degree heart block.\n    * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years old, or any concomitant medication known to prolong the QT interval (according to institutional guidelines).\n    * Ejection fraction (EF) < 55% or the lower limit of normal of the institutional standard will be excluded. Only in cases where the Investigator (or the treating physician or both) suspects cardiac disease with negative effect on the EF will the EF be measured during screening using an appropriate method according to local standards to confirm eligibility (e.g. echocardiogram [ECHO], multi-gated acquisition scan [MUGA]. A historic measurement of EF no older than 6 months prior to first study treatment administration can be accepted provided that there is clinical evidence that the EF value has not worsened since this measurement in the opinion of the Investigator or the treating physician or both.\n\nSpecific to Cohorts 3, 4a, 4b:\n\n1. Previous treatment with VSV-based agents.\n2. Use of Tamoxifen within one month prior the initiation of study treatment.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "1. Patient agrees to follow the instructions and precautions (see Section 4.4.1) related to potential VSV-GP128 shedding.",
                "criterions": [
                    {
                        "exact_snippets": "Patient agrees to follow the instructions and precautions ... related to potential VSV-GP128 shedding",
                        "criterion": "agreement to follow instructions and precautions for VSV-GP128 shedding",
                        "requirement": {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patient agrees to follow the instructions and precautions ... related to potential VSV-GP128 shedding",
                        "criterion": "agreement to follow instructions and precautions for VSV-GP128 shedding",
                        "requirement": {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "14. Hemoglobin level ≥ 9 g/dL.",
                "criterions": [
                    {
                        "exact_snippets": "Hemoglobin level ≥ 9 g/dL",
                        "criterion": "hemoglobin level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hemoglobin level ≥ 9 g/dL",
                        "criterion": "hemoglobin level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Note: Patient may have also received prior adjuvant therapy for stage II or III colorectal cancer, however the adjuvant treatment for stage II and III will not be considered as a prior line of therapy in case of relapse more than 6 months after the end of treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Patient may have also received prior adjuvant therapy for stage II or III colorectal cancer",
                        "criterion": "prior adjuvant therapy for stage II or III colorectal cancer",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "adjuvant treatment for stage II and III will not be considered as a prior line of therapy in case of relapse more than 6 months after the end of treatment",
                        "criterion": "relapse after adjuvant treatment for stage II or III colorectal cancer",
                        "requirement": {
                            "requirement_type": "time since end of adjuvant treatment to relapse",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patient may have also received prior adjuvant therapy for stage II or III colorectal cancer",
                        "criterion": "prior adjuvant therapy for stage II or III colorectal cancer",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "adjuvant treatment for stage II and III will not be considered as a prior line of therapy in case of relapse more than 6 months after the end of treatment",
                        "criterion": "relapse after adjuvant treatment for stage II or III colorectal cancer",
                        "requirement": {
                            "requirement_type": "time since end of adjuvant treatment to relapse",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "5. Must have received first line neoadjuvant SoC systemic therapy (physician choice) for stage IV disease. May have received up to 16 weeks of this systemic SoC therapy.",
                "criterions": [
                    {
                        "exact_snippets": "Must have received first line neoadjuvant SoC systemic therapy (physician choice) for stage IV disease.",
                        "criterion": "systemic therapy",
                        "requirement": {
                            "requirement_type": "line of therapy",
                            "expected_value": "first line"
                        }
                    },
                    {
                        "exact_snippets": "Must have received first line neoadjuvant SoC systemic therapy (physician choice) for stage IV disease.",
                        "criterion": "systemic therapy",
                        "requirement": {
                            "requirement_type": "setting",
                            "expected_value": "neoadjuvant"
                        }
                    },
                    {
                        "exact_snippets": "Must have received first line neoadjuvant SoC systemic therapy (physician choice) for stage IV disease.",
                        "criterion": "systemic therapy",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "SoC (standard of care)"
                        }
                    },
                    {
                        "exact_snippets": "Must have received first line neoadjuvant SoC systemic therapy (physician choice) for stage IV disease.",
                        "criterion": "systemic therapy",
                        "requirement": {
                            "requirement_type": "selection",
                            "expected_value": "physician choice"
                        }
                    },
                    {
                        "exact_snippets": "Must have received first line neoadjuvant SoC systemic therapy (physician choice) for stage IV disease.",
                        "criterion": "systemic therapy",
                        "requirement": {
                            "requirement_type": "indication",
                            "expected_value": "stage IV disease"
                        }
                    },
                    {
                        "exact_snippets": "Must have received first line neoadjuvant SoC systemic therapy (physician choice) for stage IV disease.",
                        "criterion": "systemic therapy",
                        "requirement": {
                            "requirement_type": "receipt",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "May have received up to 16 weeks of this systemic SoC therapy.",
                        "criterion": "duration of systemic SoC therapy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 16,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Must have received first line neoadjuvant SoC systemic therapy (physician choice) for stage IV disease.",
                        "criterion": "systemic therapy",
                        "requirement": {
                            "requirement_type": "line of therapy",
                            "expected_value": "first line"
                        }
                    },
                    {
                        "exact_snippets": "Must have received first line neoadjuvant SoC systemic therapy (physician choice) for stage IV disease.",
                        "criterion": "systemic therapy",
                        "requirement": {
                            "requirement_type": "setting",
                            "expected_value": "neoadjuvant"
                        }
                    },
                    {
                        "exact_snippets": "Must have received first line neoadjuvant SoC systemic therapy (physician choice) for stage IV disease.",
                        "criterion": "systemic therapy",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": "SoC (standard of care)"
                        }
                    },
                    {
                        "exact_snippets": "Must have received first line neoadjuvant SoC systemic therapy (physician choice) for stage IV disease.",
                        "criterion": "systemic therapy",
                        "requirement": {
                            "requirement_type": "selection",
                            "expected_value": "physician choice"
                        }
                    },
                    {
                        "exact_snippets": "Must have received first line neoadjuvant SoC systemic therapy (physician choice) for stage IV disease.",
                        "criterion": "systemic therapy",
                        "requirement": {
                            "requirement_type": "indication",
                            "expected_value": "stage IV disease"
                        }
                    },
                    {
                        "exact_snippets": "Must have received first line neoadjuvant SoC systemic therapy (physician choice) for stage IV disease.",
                        "criterion": "systemic therapy",
                        "requirement": {
                            "requirement_type": "receipt",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "May have received up to 16 weeks of this systemic SoC therapy.",
                        "criterion": "duration of systemic SoC therapy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 16,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to use highly effective contraceptive methods during the treatment period and for at least 180 days after the last dose of study treatment and refrain from egg donation during this period.",
                "criterions": [
                    {
                        "exact_snippets": "Not a woman of childbearing potential (WOCBP)",
                        "criterion": "woman of childbearing potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "A WOCBP who agrees to use highly effective contraceptive methods during the treatment period and for at least 180 days after the last dose of study treatment",
                        "criterion": "contraceptive use (for WOCBP)",
                        "requirement": {
                            "requirement_type": "method",
                            "expected_value": "highly effective"
                        }
                    },
                    {
                        "exact_snippets": "A WOCBP who agrees to use highly effective contraceptive methods during the treatment period and for at least 180 days after the last dose of study treatment",
                        "criterion": "contraceptive use (for WOCBP)",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 180,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "A WOCBP who agrees to ... refrain from egg donation during this period",
                        "criterion": "egg donation (for WOCBP)",
                        "requirement": {
                            "requirement_type": "refrain",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "A WOCBP who agrees to ... refrain from egg donation during this period",
                        "criterion": "egg donation (for WOCBP)",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 180,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Not a woman of childbearing potential (WOCBP)",
                        "criterion": "woman of childbearing potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "A WOCBP who agrees to use highly effective contraceptive methods during the treatment period and for at least 180 days after the last dose of study treatment",
                                "criterion": "contraceptive use (for WOCBP)",
                                "requirement": {
                                    "requirement_type": "method",
                                    "expected_value": "highly effective"
                                }
                            },
                            {
                                "exact_snippets": "A WOCBP who agrees to use highly effective contraceptive methods during the treatment period and for at least 180 days after the last dose of study treatment",
                                "criterion": "contraceptive use (for WOCBP)",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 180,
                                                "unit": "days"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "exact_snippets": "A WOCBP who agrees to ... refrain from egg donation during this period",
                                "criterion": "egg donation (for WOCBP)",
                                "requirement": {
                                    "requirement_type": "refrain",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "A WOCBP who agrees to ... refrain from egg donation during this period",
                                "criterion": "egg donation (for WOCBP)",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 180,
                                                "unit": "days"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Presence of at least one metastatic lesion amenable to paired biopsies (same lesion to be biopsied twice, at baseline and on D36), ideally not the one being used for measuring. However, liver lesions must be prioritized. Non-liver metastatic lesion biopsies may be collected only if the patient has no liver lesion or if the liver lesion is not amenable to paired biopsies (e.g. due to its size or location) or if the liver biopsy represents a risk or an undue inconvenience for the patient health/condition per Investigator judgment. In such cases, where a patient has no lesion amenable to biopsy at all, the paired biopsies may be waived by the Sponsor on a case-by-case basis.",
                "criterions": [
                    {
                        "exact_snippets": "Presence of at least one metastatic lesion amenable to paired biopsies (same lesion to be biopsied twice, at baseline and on D36)",
                        "criterion": "metastatic lesion",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Presence of at least one metastatic lesion amenable to paired biopsies (same lesion to be biopsied twice, at baseline and on D36)",
                        "criterion": "metastatic lesion",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Presence of at least one metastatic lesion amenable to paired biopsies (same lesion to be biopsied twice, at baseline and on D36)",
                        "criterion": "metastatic lesion",
                        "requirement": {
                            "requirement_type": "amenability to paired biopsies",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "liver lesions must be prioritized. Non-liver metastatic lesion biopsies may be collected only if the patient has no liver lesion or if the liver lesion is not amenable to paired biopsies (e.g. due to its size or location) or if the liver biopsy represents a risk or an undue inconvenience for the patient health/condition per Investigator judgment.",
                        "criterion": "liver lesion",
                        "requirement": {
                            "requirement_type": "priority for biopsy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "liver lesions must be prioritized. Non-liver metastatic lesion biopsies may be collected only if the patient has no liver lesion or if the liver lesion is not amenable to paired biopsies (e.g. due to its size or location) or if the liver biopsy represents a risk or an undue inconvenience for the patient health/condition per Investigator judgment.",
                        "criterion": "liver lesion",
                        "requirement": {
                            "requirement_type": "amenability to paired biopsies",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Non-liver metastatic lesion biopsies may be collected only if the patient has no liver lesion or if the liver lesion is not amenable to paired biopsies (e.g. due to its size or location) or if the liver biopsy represents a risk or an undue inconvenience for the patient health/condition per Investigator judgment.",
                        "criterion": "non-liver metastatic lesion",
                        "requirement": {
                            "requirement_type": "biopsy allowed if no liver lesion or liver lesion not amenable to paired biopsies or liver biopsy is a risk/undue inconvenience",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "where a patient has no lesion amenable to biopsy at all, the paired biopsies may be waived by the Sponsor on a case-by-case basis.",
                        "criterion": "lesion amenable to biopsy",
                        "requirement": {
                            "requirement_type": "waiver if no amenable lesion",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Presence of at least one metastatic lesion amenable to paired biopsies (same lesion to be biopsied twice, at baseline and on D36)",
                                "criterion": "metastatic lesion",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Presence of at least one metastatic lesion amenable to paired biopsies (same lesion to be biopsied twice, at baseline and on D36)",
                                "criterion": "metastatic lesion",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "lesion"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Presence of at least one metastatic lesion amenable to paired biopsies (same lesion to be biopsied twice, at baseline and on D36)",
                                "criterion": "metastatic lesion",
                                "requirement": {
                                    "requirement_type": "amenability to paired biopsies",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "or_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "liver lesions must be prioritized. Non-liver metastatic lesion biopsies may be collected only if the patient has no liver lesion or if the liver lesion is not amenable to paired biopsies (e.g. due to its size or location) or if the liver biopsy represents a risk or an undue inconvenience for the patient health/condition per Investigator judgment.",
                                        "criterion": "liver lesion",
                                        "requirement": {
                                            "requirement_type": "priority for biopsy",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "liver lesions must be prioritized. Non-liver metastatic lesion biopsies may be collected only if the patient has no liver lesion or if the liver lesion is not amenable to paired biopsies (e.g. due to its size or location) or if the liver biopsy represents a risk or an undue inconvenience for the patient health/condition per Investigator judgment.",
                                        "criterion": "liver lesion",
                                        "requirement": {
                                            "requirement_type": "amenability to paired biopsies",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            },
                            {
                                "exact_snippets": "Non-liver metastatic lesion biopsies may be collected only if the patient has no liver lesion or if the liver lesion is not amenable to paired biopsies (e.g. due to its size or location) or if the liver biopsy represents a risk or an undue inconvenience for the patient health/condition per Investigator judgment.",
                                "criterion": "non-liver metastatic lesion",
                                "requirement": {
                                    "requirement_type": "biopsy allowed if no liver lesion or liver lesion not amenable to paired biopsies or liver biopsy is a risk/undue inconvenience",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "where a patient has no lesion amenable to biopsy at all, the paired biopsies may be waived by the Sponsor on a case-by-case basis.",
                        "criterion": "lesion amenable to biopsy",
                        "requirement": {
                            "requirement_type": "waiver if no amenable lesion",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "15. Hemoglobin level ≥ 9 g/dL.",
                "criterions": [
                    {
                        "exact_snippets": "Hemoglobin level ≥ 9 g/dL",
                        "criterion": "hemoglobin level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hemoglobin level ≥ 9 g/dL",
                        "criterion": "hemoglobin level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Life expectancy of at least 3 months.",
                "criterions": [
                    {
                        "exact_snippets": "Life expectancy of at least 3 months",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Life expectancy of at least 3 months",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "15. Hemoglobin level ≥ 9 g/dL.",
                "criterions": [
                    {
                        "exact_snippets": "Hemoglobin level ≥ 9 g/dL",
                        "criterion": "hemoglobin level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Hemoglobin level ≥ 9 g/dL",
                        "criterion": "hemoglobin level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "20. A male patient must agree to use a contraceptive during the treatment period and for at least 180 days after the last dose of study treatment and refrain from donating sperm during this period.",
                "criterions": [
                    {
                        "exact_snippets": "A male patient must agree to use a contraceptive during the treatment period and for at least 180 days after the last dose of study treatment",
                        "criterion": "contraceptive use",
                        "requirement": {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "A male patient must agree to use a contraceptive during the treatment period and for at least 180 days after the last dose of study treatment",
                        "criterion": "contraceptive use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 180,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "refrain from donating sperm during this period",
                        "criterion": "sperm donation",
                        "requirement": {
                            "requirement_type": "refrain",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "refrain from donating sperm during this period",
                        "criterion": "sperm donation",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "during the treatment period and for at least 180 days after the last dose of study treatment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "A male patient must agree to use a contraceptive during the treatment period and for at least 180 days after the last dose of study treatment",
                                "criterion": "contraceptive use",
                                "requirement": {
                                    "requirement_type": "agreement",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "A male patient must agree to use a contraceptive during the treatment period and for at least 180 days after the last dose of study treatment",
                                "criterion": "contraceptive use",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 180,
                                                "unit": "days"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "refrain from donating sperm during this period",
                                "criterion": "sperm donation",
                                "requirement": {
                                    "requirement_type": "refrain",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "refrain from donating sperm during this period",
                                "criterion": "sperm donation",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": "during the treatment period and for at least 180 days after the last dose of study treatment"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Willingness to undergo two biopsies (liver lesion must be prioritized). If the Investigator judges the biopsies to be a risk or an undue inconvenience for the patient health/condition, they may be waived by the Sponsor on a case-by-case basis.",
                "criterions": [
                    {
                        "exact_snippets": "Willingness to undergo two biopsies",
                        "criterion": "willingness to undergo biopsies",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Willingness to undergo two biopsies",
                        "criterion": "willingness to undergo biopsies",
                        "requirement": {
                            "requirement_type": "number of biopsies",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "biopsies"
                            }
                        }
                    },
                    {
                        "exact_snippets": "liver lesion must be prioritized",
                        "criterion": "biopsy site prioritization",
                        "requirement": {
                            "requirement_type": "priority site",
                            "expected_value": "liver lesion"
                        }
                    },
                    {
                        "exact_snippets": "If the Investigator judges the biopsies to be a risk or an undue inconvenience for the patient health/condition, they may be waived by the Sponsor on a case-by-case basis.",
                        "criterion": "biopsy waiver eligibility",
                        "requirement": {
                            "requirement_type": "investigator judgment of risk or undue inconvenience",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "If the Investigator judges the biopsies to be a risk or an undue inconvenience for the patient health/condition, they may be waived by the Sponsor on a case-by-case basis.",
                        "criterion": "biopsy waiver eligibility",
                        "requirement": {
                            "requirement_type": "sponsor approval for waiver",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Willingness to undergo two biopsies",
                                        "criterion": "willingness to undergo biopsies",
                                        "requirement": {
                                            "requirement_type": "willingness",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "Willingness to undergo two biopsies",
                                        "criterion": "willingness to undergo biopsies",
                                        "requirement": {
                                            "requirement_type": "number of biopsies",
                                            "expected_value": {
                                                "operator": "=",
                                                "value": 2,
                                                "unit": "biopsies"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "liver lesion must be prioritized",
                                        "criterion": "biopsy site prioritization",
                                        "requirement": {
                                            "requirement_type": "priority site",
                                            "expected_value": "liver lesion"
                                        }
                                    }
                                ]
                            },
                            {
                                "not_criteria": {
                                    "and_criteria": [
                                        {
                                            "exact_snippets": "If the Investigator judges the biopsies to be a risk or an undue inconvenience for the patient health/condition, they may be waived by the Sponsor on a case-by-case basis.",
                                            "criterion": "biopsy waiver eligibility",
                                            "requirement": {
                                                "requirement_type": "investigator judgment of risk or undue inconvenience",
                                                "expected_value": true
                                            }
                                        },
                                        {
                                            "exact_snippets": "If the Investigator judges the biopsies to be a risk or an undue inconvenience for the patient health/condition, they may be waived by the Sponsor on a case-by-case basis.",
                                            "criterion": "biopsy waiver eligibility",
                                            "requirement": {
                                                "requirement_type": "sponsor approval for waiver",
                                                "expected_value": true
                                            }
                                        }
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Age ≥ 18 years.",
                "criterions": [
                    {
                        "exact_snippets": "Age ≥ 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age ≥ 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Ability to comprehend and willingness to provide written informed consent (ICF) for the study.",
                "criterions": [
                    {
                        "exact_snippets": "Ability to comprehend",
                        "criterion": "comprehension ability",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness to provide written informed consent (ICF) for the study",
                        "criterion": "willingness to provide written informed consent",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Ability to comprehend",
                        "criterion": "comprehension ability",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness to provide written informed consent (ICF) for the study",
                        "criterion": "willingness to provide written informed consent",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. ECOG performance status 0 to 2.",
                "criterions": [
                    {
                        "exact_snippets": "ECOG performance status 0 to 2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ECOG performance status 0 to 2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to use highly effective contraceptive methods during the treatment period and for at least 180 days after the last dose of study treatment and refrain from egg donation during this period.",
                "criterions": [
                    {
                        "exact_snippets": "Not a woman of childbearing potential (WOCBP)",
                        "criterion": "woman of childbearing potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "A WOCBP who agrees to use highly effective contraceptive methods during the treatment period and for at least 180 days after the last dose of study treatment",
                        "criterion": "contraceptive use",
                        "requirement": {
                            "requirement_type": "method effectiveness",
                            "expected_value": "highly effective"
                        }
                    },
                    {
                        "exact_snippets": "A WOCBP who agrees to use highly effective contraceptive methods during the treatment period and for at least 180 days after the last dose of study treatment",
                        "criterion": "contraceptive use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 180,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "A WOCBP who agrees to ... refrain from egg donation during this period",
                        "criterion": "egg donation",
                        "requirement": {
                            "requirement_type": "refrain from donation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "A WOCBP who agrees to ... refrain from egg donation during this period",
                        "criterion": "egg donation",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "during the treatment period and for at least 180 days after the last dose of study treatment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Not a woman of childbearing potential (WOCBP)",
                        "criterion": "woman of childbearing potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "A WOCBP who agrees to use highly effective contraceptive methods during the treatment period and for at least 180 days after the last dose of study treatment",
                                "criterion": "contraceptive use",
                                "requirement": {
                                    "requirement_type": "method effectiveness",
                                    "expected_value": "highly effective"
                                }
                            },
                            {
                                "exact_snippets": "A WOCBP who agrees to use highly effective contraceptive methods during the treatment period and for at least 180 days after the last dose of study treatment",
                                "criterion": "contraceptive use",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 180,
                                                "unit": "days"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "exact_snippets": "A WOCBP who agrees to ... refrain from egg donation during this period",
                                "criterion": "egg donation",
                                "requirement": {
                                    "requirement_type": "refrain from donation",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "A WOCBP who agrees to ... refrain from egg donation during this period",
                                "criterion": "egg donation",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": "during the treatment period and for at least 180 days after the last dose of study treatment"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "19. A male patient must agree to use a contraceptive during the treatment period and for at least 180 days after the last dose of study treatment and refrain from donating sperm during this period.",
                "criterions": [
                    {
                        "exact_snippets": "A male patient must agree to use a contraceptive during the treatment period and for at least 180 days after the last dose of study treatment",
                        "criterion": "contraceptive use",
                        "requirement": {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "A male patient must agree to use a contraceptive during the treatment period and for at least 180 days after the last dose of study treatment",
                        "criterion": "contraceptive use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 180,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "refrain from donating sperm during this period",
                        "criterion": "sperm donation",
                        "requirement": {
                            "requirement_type": "refrain",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "refrain from donating sperm during this period",
                        "criterion": "sperm donation",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 180,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "A male patient must agree to use a contraceptive during the treatment period and for at least 180 days after the last dose of study treatment",
                        "criterion": "contraceptive use",
                        "requirement": {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "A male patient must agree to use a contraceptive during the treatment period and for at least 180 days after the last dose of study treatment",
                        "criterion": "contraceptive use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 180,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "refrain from donating sperm during this period",
                        "criterion": "sperm donation",
                        "requirement": {
                            "requirement_type": "refrain",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "refrain from donating sperm during this period",
                        "criterion": "sperm donation",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 180,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "20. A male patient must agree to use a contraceptive during the treatment period and for at least 180 days after the last dose of study treatment and refrain from donating sperm during this period.",
                "criterions": [
                    {
                        "exact_snippets": "A male patient must agree to use a contraceptive during the treatment period and for at least 180 days after the last dose of study treatment",
                        "criterion": "contraceptive use",
                        "requirement": {
                            "requirement_type": "agreement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "A male patient must agree to use a contraceptive during the treatment period and for at least 180 days after the last dose of study treatment",
                        "criterion": "contraceptive use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 180,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "refrain from donating sperm during this period",
                        "criterion": "sperm donation",
                        "requirement": {
                            "requirement_type": "refrain",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "refrain from donating sperm during this period",
                        "criterion": "sperm donation",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 180,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "A male patient must agree to use a contraceptive during the treatment period and for at least 180 days after the last dose of study treatment",
                                "criterion": "contraceptive use",
                                "requirement": {
                                    "requirement_type": "agreement",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "A male patient must agree to use a contraceptive during the treatment period and for at least 180 days after the last dose of study treatment",
                                "criterion": "contraceptive use",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 180,
                                                "unit": "days"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "refrain from donating sperm during this period",
                                "criterion": "sperm donation",
                                "requirement": {
                                    "requirement_type": "refrain",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "refrain from donating sperm during this period",
                                "criterion": "sperm donation",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 180,
                                                "unit": "days"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "17. ALT/AST ≤ 2.5 × ULN or ≤ 5 × ULN in patients with hepatic involvement.",
                "criterions": [
                    {
                        "exact_snippets": "ALT/AST ≤ 2.5 × ULN or ≤ 5 × ULN in patients with hepatic involvement",
                        "criterion": "ALT",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "ALT/AST ≤ 2.5 × ULN or ≤ 5 × ULN in patients with hepatic involvement",
                        "criterion": "AST",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "≤ 5 × ULN in patients with hepatic involvement",
                        "criterion": "ALT in patients with hepatic involvement",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "≤ 5 × ULN in patients with hepatic involvement",
                        "criterion": "AST in patients with hepatic involvement",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "ALT/AST ≤ 2.5 × ULN or ≤ 5 × ULN in patients with hepatic involvement",
                                "criterion": "ALT",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 2.5,
                                                "unit": "ULN"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "exact_snippets": "ALT/AST ≤ 2.5 × ULN or ≤ 5 × ULN in patients with hepatic involvement",
                                "criterion": "AST",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 2.5,
                                                "unit": "ULN"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "≤ 5 × ULN in patients with hepatic involvement",
                                "criterion": "ALT in patients with hepatic involvement",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 5,
                                                "unit": "ULN"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "exact_snippets": "≤ 5 × ULN in patients with hepatic involvement",
                                "criterion": "AST in patients with hepatic involvement",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 5,
                                                "unit": "ULN"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Not a woman of childbearing potential (WOCBP) OR A WOCBP who agrees to use highly effective contraceptive methods during the treatment period and for at least 180 days after the last dose of study treatment and refrain from egg donation during this period.",
                "criterions": [
                    {
                        "exact_snippets": "Not a woman of childbearing potential (WOCBP)",
                        "criterion": "woman of childbearing potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "A WOCBP who agrees to use highly effective contraceptive methods during the treatment period and for at least 180 days after the last dose of study treatment",
                        "criterion": "contraceptive use",
                        "requirement": {
                            "requirement_type": "method effectiveness",
                            "expected_value": "highly effective"
                        }
                    },
                    {
                        "exact_snippets": "A WOCBP who agrees to use highly effective contraceptive methods during the treatment period and for at least 180 days after the last dose of study treatment",
                        "criterion": "contraceptive use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 180,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "A WOCBP who agrees to ... refrain from egg donation during this period",
                        "criterion": "egg donation",
                        "requirement": {
                            "requirement_type": "refrain from",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "A WOCBP who agrees to ... refrain from egg donation during this period",
                        "criterion": "egg donation",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "during the treatment period and for at least 180 days after the last dose of study treatment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Not a woman of childbearing potential (WOCBP)",
                        "criterion": "woman of childbearing potential",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "A WOCBP who agrees to use highly effective contraceptive methods during the treatment period and for at least 180 days after the last dose of study treatment",
                                "criterion": "contraceptive use",
                                "requirement": {
                                    "requirement_type": "method effectiveness",
                                    "expected_value": "highly effective"
                                }
                            },
                            {
                                "exact_snippets": "A WOCBP who agrees to use highly effective contraceptive methods during the treatment period and for at least 180 days after the last dose of study treatment",
                                "criterion": "contraceptive use",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 180,
                                                "unit": "days"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "exact_snippets": "A WOCBP who agrees to ... refrain from egg donation during this period",
                                "criterion": "egg donation",
                                "requirement": {
                                    "requirement_type": "refrain from",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "A WOCBP who agrees to ... refrain from egg donation during this period",
                                "criterion": "egg donation",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": "during the treatment period and for at least 180 days after the last dose of study treatment"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Life expectancy of at least 12 months.",
                "criterions": [
                    {
                        "exact_snippets": "Life expectancy of at least 12 months",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Life expectancy of at least 12 months",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Absence of disease progression following neoadjuvant chemotherapy.",
                "criterions": [
                    {
                        "exact_snippets": "Absence of disease progression following neoadjuvant chemotherapy",
                        "criterion": "disease progression following neoadjuvant chemotherapy",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absence of disease progression following neoadjuvant chemotherapy",
                        "criterion": "disease progression following neoadjuvant chemotherapy",
                        "requirement": {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "19. A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:",
                "criterions": [
                    {
                        "exact_snippets": "female patient",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "not pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "not breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "female patient",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "not pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "not breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "11. Adequate renal, hepatic, and hematologic functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                "criterions": [
                    {
                        "exact_snippets": "Adequate renal ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate renal ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "assessment_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before study treatment initiation"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... hepatic ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... hepatic ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "assessment_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before study treatment initiation"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... hematologic functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "hematologic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... hematologic functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "hematologic function",
                        "requirement": {
                            "requirement_type": "assessment_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before study treatment initiation"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Adequate renal ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "renal function",
                                "requirement": {
                                    "requirement_type": "adequacy",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Adequate renal ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "renal function",
                                "requirement": {
                                    "requirement_type": "assessment_timing",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days before study treatment initiation"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Adequate ... hepatic ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "hepatic function",
                                "requirement": {
                                    "requirement_type": "adequacy",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Adequate ... hepatic ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "hepatic function",
                                "requirement": {
                                    "requirement_type": "assessment_timing",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days before study treatment initiation"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Adequate ... hematologic functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "hematologic function",
                                "requirement": {
                                    "requirement_type": "adequacy",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Adequate ... hematologic functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "hematologic function",
                                "requirement": {
                                    "requirement_type": "assessment_timing",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days before study treatment initiation"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Age ≥ 18 years.",
                "criterions": [
                    {
                        "exact_snippets": "Age ≥ 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age ≥ 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "N/A",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Cohort 1a",
                "criterions": [
                    {
                        "exact_snippets": "Cohort 1a",
                        "criterion": "cohort assignment",
                        "requirement": {
                            "requirement_type": "cohort",
                            "expected_value": "1a"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Cohort 1a",
                        "criterion": "cohort assignment",
                        "requirement": {
                            "requirement_type": "cohort",
                            "expected_value": "1a"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Ability to comprehend and willingness to provide written informed consent (ICF) for the study.",
                "criterions": [
                    {
                        "exact_snippets": "Ability to comprehend",
                        "criterion": "comprehension ability",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness to provide written informed consent (ICF) for the study",
                        "criterion": "willingness to provide written informed consent",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Ability to comprehend",
                        "criterion": "comprehension ability",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness to provide written informed consent (ICF) for the study",
                        "criterion": "willingness to provide written informed consent",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "11. Adequate renal, hepatic, thyroid and hematologic functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                "criterions": [
                    {
                        "exact_snippets": "Adequate renal ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate renal ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "assessment_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before study treatment initiation"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... hepatic ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... hepatic ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "assessment_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before study treatment initiation"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... thyroid ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "thyroid function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... thyroid ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "thyroid function",
                        "requirement": {
                            "requirement_type": "assessment_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before study treatment initiation"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... hematologic functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "hematologic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... hematologic functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "hematologic function",
                        "requirement": {
                            "requirement_type": "assessment_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days before study treatment initiation"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Adequate renal ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "renal function",
                                "requirement": {
                                    "requirement_type": "adequacy",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Adequate renal ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "renal function",
                                "requirement": {
                                    "requirement_type": "assessment_timing",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days before study treatment initiation"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Adequate ... hepatic ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "hepatic function",
                                "requirement": {
                                    "requirement_type": "adequacy",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Adequate ... hepatic ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "hepatic function",
                                "requirement": {
                                    "requirement_type": "assessment_timing",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days before study treatment initiation"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Adequate ... thyroid ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "thyroid function",
                                "requirement": {
                                    "requirement_type": "adequacy",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Adequate ... thyroid ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "thyroid function",
                                "requirement": {
                                    "requirement_type": "assessment_timing",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days before study treatment initiation"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Adequate ... hematologic functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "hematologic function",
                                "requirement": {
                                    "requirement_type": "adequacy",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Adequate ... hematologic functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "hematologic function",
                                "requirement": {
                                    "requirement_type": "assessment_timing",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 7,
                                        "unit": "days before study treatment initiation"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "16. Total bilirubin ≤ 1.5 × ULN; if total bilirubin is > 1.5 x ULN then direct bilirubin must be ≤ 1.5 × ULN. Patients with known Gilbert's Syndrome may enroll if total bilirubin ≤ 3 × ULN.",
                "criterions": [
                    {
                        "exact_snippets": "Total bilirubin ≤ 1.5 × ULN",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "if total bilirubin is > 1.5 x ULN then direct bilirubin must be ≤ 1.5 × ULN",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Patients with known Gilbert's Syndrome may enroll if total bilirubin ≤ 3 × ULN",
                        "criterion": "total bilirubin in patients with known Gilbert's Syndrome",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Patients with known Gilbert's Syndrome may enroll if total bilirubin ≤ 3 × ULN",
                        "criterion": "total bilirubin in patients with known Gilbert's Syndrome",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Total bilirubin ≤ 1.5 × ULN",
                                "criterion": "total bilirubin",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "ULN"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "if total bilirubin is > 1.5 x ULN then direct bilirubin must be ≤ 1.5 × ULN",
                                "criterion": "direct bilirubin",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "ULN"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "18. Alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 2.5 × ULN or ≤ 5 x ULN in patients with hepatic involvement.",
                "criterions": [
                    {
                        "exact_snippets": "Alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 2.5 × ULN or ≤ 5 x ULN in patients with hepatic involvement.",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 2.5 × ULN or ≤ 5 x ULN in patients with hepatic involvement.",
                        "criterion": "aspartate aminotransferase (AST) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "≤ 5 x ULN in patients with hepatic involvement",
                        "criterion": "alanine aminotransferase (ALT) level in patients with hepatic involvement",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "≤ 5 x ULN in patients with hepatic involvement",
                        "criterion": "aspartate aminotransferase (AST) level in patients with hepatic involvement",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 2.5 × ULN or ≤ 5 x ULN in patients with hepatic involvement.",
                                "criterion": "alanine aminotransferase (ALT) level",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 2.5,
                                                "unit": "ULN"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 2.5 × ULN or ≤ 5 x ULN in patients with hepatic involvement.",
                                "criterion": "aspartate aminotransferase (AST) level",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 2.5,
                                                "unit": "ULN"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "≤ 5 x ULN in patients with hepatic involvement",
                                "criterion": "alanine aminotransferase (ALT) level in patients with hepatic involvement",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 5,
                                                "unit": "ULN"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "exact_snippets": "≤ 5 x ULN in patients with hepatic involvement",
                                "criterion": "aspartate aminotransferase (AST) level in patients with hepatic involvement",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 5,
                                                "unit": "ULN"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Presence of at least one liver lesion amenable to repeated biopsy, ideally not the one being used for measuring.",
                "criterions": [
                    {
                        "exact_snippets": "Presence of at least one liver lesion",
                        "criterion": "liver lesion",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Presence of at least one liver lesion",
                        "criterion": "liver lesion",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    },
                    {
                        "exact_snippets": "liver lesion amenable to repeated biopsy",
                        "criterion": "liver lesion amenability to repeated biopsy",
                        "requirement": {
                            "requirement_type": "amenability to repeated biopsy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Presence of at least one liver lesion",
                        "criterion": "liver lesion",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Presence of at least one liver lesion",
                        "criterion": "liver lesion",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    },
                    {
                        "exact_snippets": "liver lesion amenable to repeated biopsy",
                        "criterion": "liver lesion amenability to repeated biopsy",
                        "requirement": {
                            "requirement_type": "amenability to repeated biopsy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "18. A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:",
                "criterions": [
                    {
                        "exact_snippets": "female patient",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "not pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "not breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "female patient",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "not pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "not breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "16. Measured or calculated creatinine clearance (glomerular filtration rate can also be used in place of creatinine clearance) ≥ 50 mL/min according to the formula of Cockcroft-Gault (see Appendix 6).",
                "criterions": [
                    {
                        "exact_snippets": "Measured or calculated creatinine clearance ... ≥ 50 mL/min",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "glomerular filtration rate can also be used in place of creatinine clearance ... ≥ 50 mL/min",
                        "criterion": "glomerular filtration rate",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Measured or calculated creatinine clearance ... ≥ 50 mL/min",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "glomerular filtration rate can also be used in place of creatinine clearance ... ≥ 50 mL/min",
                        "criterion": "glomerular filtration rate",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Age ≥ 18 years.",
                "criterions": [
                    {
                        "exact_snippets": "Age ≥ 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Age ≥ 18 years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "13. Platelets ≥ 100 × 109/L.",
                "criterions": [
                    {
                        "exact_snippets": "Platelets ≥ 100 × 10^9/L.",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "× 10^9/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelets ≥ 100 × 10^9/L.",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "× 10^9/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "12. Absolute lymphocyte count ≥ 0.5 × 109 /L.",
                "criterions": [
                    {
                        "exact_snippets": "Absolute lymphocyte count ≥ 0.5 × 10^9 /L.",
                        "criterion": "absolute lymphocyte count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "10^9/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute lymphocyte count ≥ 0.5 × 10^9 /L.",
                        "criterion": "absolute lymphocyte count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "10^9/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Ability to comprehend and willingness to provide written informed consent (ICF) for the study.",
                "criterions": [
                    {
                        "exact_snippets": "Ability to comprehend",
                        "criterion": "comprehension ability",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness to provide written informed consent (ICF) for the study",
                        "criterion": "willingness to provide written informed consent",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Ability to comprehend",
                        "criterion": "comprehension ability",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness to provide written informed consent (ICF) for the study",
                        "criterion": "willingness to provide written informed consent",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "17. Total bilirubin ≤ 1.5 × ULN; if total bilirubin is > 1.5 x ULN then direct bilirubin must be ≤ 1.5 × ULN. Patients with known Gilbert's Syndrome may enroll if total bilirubin ≤ 3 × ULN.",
                "criterions": [
                    {
                        "exact_snippets": "Total bilirubin ≤ 1.5 × ULN",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "if total bilirubin is > 1.5 x ULN then direct bilirubin must be ≤ 1.5 × ULN",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Patients with known Gilbert's Syndrome may enroll if total bilirubin ≤ 3 × ULN",
                        "criterion": "total bilirubin in patients with known Gilbert's Syndrome",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Total bilirubin ≤ 1.5 × ULN",
                                "criterion": "total bilirubin",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "ULN"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "not_criteria": {
                                    "exact_snippets": "Total bilirubin ≤ 1.5 × ULN",
                                    "criterion": "total bilirubin",
                                    "requirement": {
                                        "requirement_type": "quantity",
                                        "expected_value": {
                                            "operator": "<=",
                                            "value": 1.5,
                                            "unit": "ULN"
                                        }
                                    }
                                }
                            },
                            {
                                "exact_snippets": "if total bilirubin is > 1.5 x ULN then direct bilirubin must be ≤ 1.5 × ULN",
                                "criterion": "direct bilirubin",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "ULN"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Patients with known Gilbert's Syndrome may enroll if total bilirubin ≤ 3 × ULN",
                                "criterion": "total bilirubin in patients with known Gilbert's Syndrome",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "ULN"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Life expectancy of at least 6 months.",
                "criterions": [
                    {
                        "exact_snippets": "Life expectancy of at least 6 months",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Life expectancy of at least 6 months",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "18. ALT/AST ≤ 2.5 × ULN or ≤ 5 × ULN in patients with hepatic involvement.",
                "criterions": [
                    {
                        "exact_snippets": "ALT/AST ≤ 2.5 × ULN or ≤ 5 × ULN in patients with hepatic involvement",
                        "criterion": "ALT",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "ALT/AST ≤ 2.5 × ULN or ≤ 5 × ULN in patients with hepatic involvement",
                        "criterion": "AST",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "≤ 5 × ULN in patients with hepatic involvement",
                        "criterion": "ALT in patients with hepatic involvement",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "≤ 5 × ULN in patients with hepatic involvement",
                        "criterion": "AST in patients with hepatic involvement",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "ALT/AST ≤ 2.5 × ULN or ≤ 5 × ULN in patients with hepatic involvement",
                                "criterion": "ALT",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 2.5,
                                                "unit": "ULN"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "exact_snippets": "ALT/AST ≤ 2.5 × ULN or ≤ 5 × ULN in patients with hepatic involvement",
                                "criterion": "AST",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 2.5,
                                                "unit": "ULN"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "≤ 5 × ULN in patients with hepatic involvement",
                                "criterion": "ALT in patients with hepatic involvement",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 5,
                                                "unit": "ULN"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "exact_snippets": "≤ 5 × ULN in patients with hepatic involvement",
                                "criterion": "AST in patients with hepatic involvement",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": "<=",
                                                "value": 5,
                                                "unit": "ULN"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. ECOG performance status 0 to 2.",
                "criterions": [
                    {
                        "exact_snippets": "ECOG performance status 0 to 2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ECOG performance status 0 to 2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Adequate renal, hepatic, thyroid and hematologic functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                "criterions": [
                    {
                        "exact_snippets": "Adequate renal ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate renal ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "renal function",
                        "requirement": {
                            "requirement_type": "assessment_timing",
                            "expected_value": "≤ 7 days before study treatment initiation"
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... hepatic ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... hepatic ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "hepatic function",
                        "requirement": {
                            "requirement_type": "assessment_timing",
                            "expected_value": "≤ 7 days before study treatment initiation"
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... thyroid ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "thyroid function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... thyroid ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "thyroid function",
                        "requirement": {
                            "requirement_type": "assessment_timing",
                            "expected_value": "≤ 7 days before study treatment initiation"
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... hematologic functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "hematologic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Adequate ... hematologic functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                        "criterion": "hematologic function",
                        "requirement": {
                            "requirement_type": "assessment_timing",
                            "expected_value": "≤ 7 days before study treatment initiation"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Adequate renal ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "renal function",
                                "requirement": {
                                    "requirement_type": "adequacy",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Adequate renal ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "renal function",
                                "requirement": {
                                    "requirement_type": "assessment_timing",
                                    "expected_value": "≤ 7 days before study treatment initiation"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Adequate ... hepatic ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "hepatic function",
                                "requirement": {
                                    "requirement_type": "adequacy",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Adequate ... hepatic ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "hepatic function",
                                "requirement": {
                                    "requirement_type": "assessment_timing",
                                    "expected_value": "≤ 7 days before study treatment initiation"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Adequate ... thyroid ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "thyroid function",
                                "requirement": {
                                    "requirement_type": "adequacy",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Adequate ... thyroid ... functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "thyroid function",
                                "requirement": {
                                    "requirement_type": "assessment_timing",
                                    "expected_value": "≤ 7 days before study treatment initiation"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Adequate ... hematologic functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "hematologic function",
                                "requirement": {
                                    "requirement_type": "adequacy",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Adequate ... hematologic functions as defined by laboratory parameters ≤ 7 days before study treatment initiation.",
                                "criterion": "hematologic function",
                                "requirement": {
                                    "requirement_type": "assessment_timing",
                                    "expected_value": "≤ 7 days before study treatment initiation"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "19. A female patient is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:",
                "criterions": [
                    {
                        "exact_snippets": "female patient",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "not pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "not breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "female patient",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "not pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "not breastfeeding",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "breastfeeding",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "14. Platelets ≥ 100 × 109/L.",
                "criterions": [
                    {
                        "exact_snippets": "Platelets ≥ 100 × 10^9/L.",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "10^9/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelets ≥ 100 × 10^9/L.",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "10^9/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Note: Patient may have also received prior adjuvant therapy for stage II or III colorectal cancer, however the adjuvant treatment for stage II and III will not be considered as a prior line of therapy in case of relapse more than 6 months after the end of treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Patient may have also received prior adjuvant therapy for stage II or III colorectal cancer",
                        "criterion": "prior adjuvant therapy for stage II or III colorectal cancer",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "adjuvant treatment for stage II and III will not be considered as a prior line of therapy in case of relapse more than 6 months after the end of treatment",
                        "criterion": "relapse after adjuvant treatment for stage II or III colorectal cancer",
                        "requirement": {
                            "requirement_type": "time since end of adjuvant treatment to relapse",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "adjuvant treatment for stage II and III will not be considered as a prior line of therapy in case of relapse more than 6 months after the end of treatment",
                        "criterion": "relapse after adjuvant treatment for stage II or III colorectal cancer",
                        "requirement": {
                            "requirement_type": "prior line of therapy status",
                            "expected_value": "not considered prior line if relapse >6 months after end of adjuvant treatment"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patient may have also received prior adjuvant therapy for stage II or III colorectal cancer",
                        "criterion": "prior adjuvant therapy for stage II or III colorectal cancer",
                        "requirement": {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    },
                    {
                        "condition": {
                            "exact_snippets": "adjuvant treatment for stage II and III will not be considered as a prior line of therapy in case of relapse more than 6 months after the end of treatment",
                            "criterion": "relapse after adjuvant treatment for stage II or III colorectal cancer",
                            "requirement": {
                                "requirement_type": "time since end of adjuvant treatment to relapse",
                                "expected_value": {
                                    "operator": ">",
                                    "value": 6,
                                    "unit": "months"
                                }
                            }
                        },
                        "then_criteria": {
                            "exact_snippets": "adjuvant treatment for stage II and III will not be considered as a prior line of therapy in case of relapse more than 6 months after the end of treatment",
                            "criterion": "relapse after adjuvant treatment for stage II or III colorectal cancer",
                            "requirement": {
                                "requirement_type": "prior line of therapy status",
                                "expected_value": "not considered prior line if relapse >6 months after end of adjuvant treatment"
                            }
                        },
                        "else_criteria": null
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "18. Known active CNS metastasis and/or carcinomatous meningitis.",
                "criterions": [
                    {
                        "exact_snippets": "Known active CNS metastasis",
                        "criterion": "CNS metastasis",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known active CNS metastasis",
                        "criterion": "CNS metastasis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "carcinomatous meningitis",
                        "criterion": "carcinomatous meningitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Known active CNS metastasis",
                                "criterion": "CNS metastasis",
                                "requirement": {
                                    "requirement_type": "activity",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Known active CNS metastasis",
                                "criterion": "CNS metastasis",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "carcinomatous meningitis",
                        "criterion": "carcinomatous meningitis",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "24. History of pneumonitis within the last 5 years.",
                "criterions": [
                    {
                        "exact_snippets": "History of pneumonitis within the last 5 years.",
                        "criterion": "pneumonitis",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "History of pneumonitis within the last 5 years.",
                        "criterion": "pneumonitis",
                        "requirement": {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "16. Known medical history of human immunodeficiency virus (HIV) infection or known medical history of acquired immunodeficiency syndrome (AIDS). HIV testing is not required unless mandated by the local health authority.",
                "criterions": [
                    {
                        "exact_snippets": "Known medical history of human immunodeficiency virus (HIV) infection",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "medical history presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known medical history of acquired immunodeficiency syndrome (AIDS)",
                        "criterion": "AIDS",
                        "requirement": {
                            "requirement_type": "medical history presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Known medical history of human immunodeficiency virus (HIV) infection",
                        "criterion": "HIV infection",
                        "requirement": {
                            "requirement_type": "medical history presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "known medical history of acquired immunodeficiency syndrome (AIDS)",
                        "criterion": "AIDS",
                        "requirement": {
                            "requirement_type": "medical history presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "8. Major (according the Investigator's judgment) surgery within 12 weeks before enrolment.",
                "criterions": [
                    {
                        "exact_snippets": "Major (according the Investigator's judgment) surgery within 12 weeks before enrolment.",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "weeks before enrolment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Major (according the Investigator's judgment) surgery within 12 weeks before enrolment.",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "major (according the Investigator's judgment)"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Major (according the Investigator's judgment) surgery within 12 weeks before enrolment.",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "weeks before enrolment"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Major (according the Investigator's judgment) surgery within 12 weeks before enrolment.",
                        "criterion": "major surgery",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": "major (according the Investigator's judgment)"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "21. History of allergy or hypersensitivity to any of the study drugs or study drug components.",
                "criterions": [
                    {
                        "exact_snippets": "History of allergy or hypersensitivity to any of the study drugs",
                        "criterion": "allergy or hypersensitivity to study drugs",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of allergy or hypersensitivity to any of the ... study drug components",
                        "criterion": "allergy or hypersensitivity to study drug components",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of allergy or hypersensitivity to any of the study drugs",
                        "criterion": "allergy or hypersensitivity to study drugs",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of allergy or hypersensitivity to any of the ... study drug components",
                        "criterion": "allergy or hypersensitivity to study drug components",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "25. Active interstitial lung disease (ILD)/pneumonitis or a history of ILD/pneumonitis requiring treatment with systemic steroids and/or whose pulse oximetry is less than 92% \"on room air\".",
                "criterions": [
                    {
                        "exact_snippets": "Active interstitial lung disease (ILD)/pneumonitis",
                        "criterion": "interstitial lung disease (ILD)/pneumonitis",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of ILD/pneumonitis requiring treatment with systemic steroids",
                        "criterion": "history of ILD/pneumonitis",
                        "requirement": {
                            "requirement_type": "treatment with systemic steroids",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "pulse oximetry is less than 92% \"on room air\"",
                        "criterion": "pulse oximetry",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 92,
                                "unit": "%"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Active interstitial lung disease (ILD)/pneumonitis",
                        "criterion": "interstitial lung disease (ILD)/pneumonitis",
                        "requirement": {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of ILD/pneumonitis requiring treatment with systemic steroids",
                        "criterion": "history of ILD/pneumonitis",
                        "requirement": {
                            "requirement_type": "treatment with systemic steroids",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "pulse oximetry is less than 92% \"on room air\"",
                        "criterion": "pulse oximetry",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<",
                                "value": 92,
                                "unit": "%"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "14. Dermatological disease requiring local immunosuppressive agent.",
                "criterions": [
                    {
                        "exact_snippets": "Dermatological disease requiring local immunosuppressive agent",
                        "criterion": "dermatological disease",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requires local immunosuppressive agent"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Dermatological disease requiring local immunosuppressive agent",
                        "criterion": "dermatological disease",
                        "requirement": {
                            "requirement_type": "treatment requirement",
                            "expected_value": "requires local immunosuppressive agent"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Previous treatment with VSV-based agents.",
                "criterions": [
                    {
                        "exact_snippets": "Previous treatment with VSV-based agents.",
                        "criterion": "previous treatment with VSV-based agents",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Previous treatment with VSV-based agents.",
                    "criterion": "previous treatment with VSV-based agents",
                    "requirement": {
                        "requirement_type": "history",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Mean resting corrected QT interval (QTc) > 470 msec.",
                "criterions": [
                    {
                        "exact_snippets": "Mean resting corrected QT interval (QTc) > 470 msec.",
                        "criterion": "corrected QT interval (QTc)",
                        "requirement": {
                            "requirement_type": "mean resting value",
                            "expected_value": {
                                "operator": ">",
                                "value": 470,
                                "unit": "msec"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Mean resting corrected QT interval (QTc) > 470 msec.",
                        "criterion": "corrected QT interval (QTc)",
                        "requirement": {
                            "requirement_type": "mean resting value",
                            "expected_value": {
                                "operator": ">",
                                "value": 470,
                                "unit": "msec"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "23. Has received more than 1 line of therapy for stage IV disease (neoadjuvant therapy in Cohort 2b counts as 1 line).",
                "criterions": [
                    {
                        "exact_snippets": "Has received more than 1 line of therapy for stage IV disease",
                        "criterion": "lines of therapy for stage IV disease",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Has received more than 1 line of therapy for stage IV disease",
                        "criterion": "lines of therapy for stage IV disease",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "26. Any of the following cardiac criteria:",
                "criterions": [
                    {
                        "exact_snippets": "Any of the following cardiac criteria",
                        "criterion": "cardiac criteria",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Any of the following cardiac criteria",
                        "criterion": "cardiac criteria",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years old, or any concomitant medication known to prolong the QT interval (according to institutional guidelines).",
                "criterions": [
                    {
                        "exact_snippets": "Any factors that increase the risk of QTc prolongation",
                        "criterion": "risk of QTc prolongation",
                        "requirement": {
                            "requirement_type": "risk_increase",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "risk of arrhythmic events",
                        "criterion": "risk of arrhythmic events",
                        "requirement": {
                            "requirement_type": "risk_increase",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "heart failure",
                        "criterion": "heart failure",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "hypokalemia",
                        "criterion": "hypokalemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "congenital long QT syndrome",
                        "criterion": "congenital long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "family history of long QT syndrome",
                        "criterion": "family history of long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "family history of ... unexplained sudden death under 40 years old",
                        "criterion": "family history of unexplained sudden death under 40 years old",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any concomitant medication known to prolong the QT interval (according to institutional guidelines)",
                        "criterion": "concomitant medication known to prolong the QT interval",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Any factors that increase the risk of QTc prolongation",
                        "criterion": "risk of QTc prolongation",
                        "requirement": {
                            "requirement_type": "risk_increase",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "risk of arrhythmic events",
                        "criterion": "risk of arrhythmic events",
                        "requirement": {
                            "requirement_type": "risk_increase",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "heart failure",
                        "criterion": "heart failure",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "hypokalemia",
                        "criterion": "hypokalemia",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "congenital long QT syndrome",
                        "criterion": "congenital long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "family history of long QT syndrome",
                        "criterion": "family history of long QT syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "family history of ... unexplained sudden death under 40 years old",
                        "criterion": "family history of unexplained sudden death under 40 years old",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any concomitant medication known to prolong the QT interval (according to institutional guidelines)",
                        "criterion": "concomitant medication known to prolong the QT interval",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "17. Has known history of or is positive for hepatitis B (hepatitis B virus surface antigen [HBsAg] reactive) or hepatitis C (HCV RNA).",
                "criterions": [
                    {
                        "exact_snippets": "Has known history of ... hepatitis B",
                        "criterion": "hepatitis B infection",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "hepatitis B virus surface antigen [HBsAg] reactive",
                        "criterion": "hepatitis B virus surface antigen (HBsAg)",
                        "requirement": {
                            "requirement_type": "reactivity",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Has known history of ... hepatitis C",
                        "criterion": "hepatitis C infection",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "hepatitis C (HCV RNA)",
                        "criterion": "hepatitis C virus RNA (HCV RNA)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "Has known history of ... hepatitis B",
                                "criterion": "hepatitis B infection",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "hepatitis B virus surface antigen [HBsAg] reactive",
                                "criterion": "hepatitis B virus surface antigen (HBsAg)",
                                "requirement": {
                                    "requirement_type": "reactivity",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "Has known history of ... hepatitis C",
                                "criterion": "hepatitis C infection",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "hepatitis C (HCV RNA)",
                                "criterion": "hepatitis C virus RNA (HCV RNA)",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "19. Known cerebral oedema.",
                "criterions": [
                    {
                        "exact_snippets": "Known cerebral oedema.",
                        "criterion": "cerebral oedema",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known cerebral oedema.",
                        "criterion": "cerebral oedema",
                        "requirement": {
                            "requirement_type": "awareness/status",
                            "expected_value": "known"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Known cerebral oedema.",
                                "criterion": "cerebral oedema",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Known cerebral oedema.",
                                "criterion": "cerebral oedema",
                                "requirement": {
                                    "requirement_type": "awareness/status",
                                    "expected_value": "known"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "22. Any condition in the judgment of the Investigator which makes the patient unsuitable for trial participation.",
                "criterions": [
                    {
                        "exact_snippets": "Any condition in the judgment of the Investigator which makes the patient unsuitable for trial participation.",
                        "criterion": "any condition making patient unsuitable for trial participation",
                        "requirement": {
                            "requirement_type": "investigator judgment of suitability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Any condition in the judgment of the Investigator which makes the patient unsuitable for trial participation.",
                        "criterion": "any condition making patient unsuitable for trial participation",
                        "requirement": {
                            "requirement_type": "investigator judgment of suitability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "10. Immunosuppression including the continued use of systemic (at prednisone dose equivalent of > 10 mg) or topical steroids at or near the injection site (excluding inhaled and eye drop-containing corticosteroids) or the use of immunosuppressive agents for any concurrent condition. All other corticosteroids must be discontinued > 4 weeks prior to first study treatment administration.",
                "criterions": [
                    {
                        "exact_snippets": "Immunosuppression including the continued use of systemic (at prednisone dose equivalent of > 10 mg)",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg prednisone equivalent"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Immunosuppression including the continued use of systemic (at prednisone dose equivalent of > 10 mg)",
                        "criterion": "systemic corticosteroid use",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "continued use"
                        }
                    },
                    {
                        "exact_snippets": "continued use of ... topical steroids at or near the injection site",
                        "criterion": "topical steroid use at or near injection site",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "continued use"
                        }
                    },
                    {
                        "exact_snippets": "use of immunosuppressive agents for any concurrent condition",
                        "criterion": "immunosuppressive agent use for concurrent condition",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "All other corticosteroids must be discontinued > 4 weeks prior to first study treatment administration.",
                        "criterion": "other corticosteroid use",
                        "requirement": {
                            "requirement_type": "discontinuation time before study treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Immunosuppression including the continued use of systemic (at prednisone dose equivalent of > 10 mg)",
                                "criterion": "systemic corticosteroid use",
                                "requirement": {
                                    "requirement_type": "dose",
                                    "expected_value": {
                                        "operator": ">",
                                        "value": 10,
                                        "unit": "mg prednisone equivalent"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Immunosuppression including the continued use of systemic (at prednisone dose equivalent of > 10 mg)",
                                "criterion": "systemic corticosteroid use",
                                "requirement": {
                                    "requirement_type": "duration",
                                    "expected_value": "continued use"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "continued use of ... topical steroids at or near the injection site",
                        "criterion": "topical steroid use at or near injection site",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": "continued use"
                        }
                    },
                    {
                        "exact_snippets": "use of immunosuppressive agents for any concurrent condition",
                        "criterion": "immunosuppressive agent use for concurrent condition",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "All other corticosteroids must be discontinued > 4 weeks prior to first study treatment administration.",
                        "criterion": "other corticosteroid use",
                        "requirement": {
                            "requirement_type": "discontinuation time before study treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "1. Unwilling or unable to follow protocol requirements or to give informed consent.",
                "criterions": [
                    {
                        "exact_snippets": "Unwilling ... to follow protocol requirements",
                        "criterion": "willingness to follow protocol requirements",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unable to follow protocol requirements",
                        "criterion": "ability to follow protocol requirements",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unwilling ... to give informed consent",
                        "criterion": "willingness to give informed consent",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "unable to ... give informed consent",
                        "criterion": "ability to give informed consent",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "not_criteria": {
                            "exact_snippets": "Unwilling ... to follow protocol requirements",
                            "criterion": "willingness to follow protocol requirements",
                            "requirement": {
                                "requirement_type": "willingness",
                                "expected_value": true
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "unable to follow protocol requirements",
                            "criterion": "ability to follow protocol requirements",
                            "requirement": {
                                "requirement_type": "ability",
                                "expected_value": true
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "unwilling ... to give informed consent",
                            "criterion": "willingness to give informed consent",
                            "requirement": {
                                "requirement_type": "willingness",
                                "expected_value": true
                            }
                        }
                    },
                    {
                        "not_criteria": {
                            "exact_snippets": "unable to ... give informed consent",
                            "criterion": "ability to give informed consent",
                            "requirement": {
                                "requirement_type": "ability",
                                "expected_value": true
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Specific to Cohorts 3, 4a, 4b:",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "All Cohorts:",
                "criterions": []
            },
            "logical_structure": {
                "and_criteria": []
            }
        },
        {
            "identified_line": {
                "line": "2. Use of Tamoxifen within one month prior the initiation of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Use of Tamoxifen within one month prior the initiation of study treatment.",
                        "criterion": "Tamoxifen use",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month prior to initiation of study treatment"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Use of Tamoxifen within one month prior the initiation of study treatment.",
                        "criterion": "Tamoxifen use",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month prior to initiation of study treatment"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any clinically important abnormalities (as assessed by the Investigator) in rhythm, conduction, or morphology of resting ECGs, e.g., complete left bundle branch block, third degree heart block.",
                "criterions": [
                    {
                        "exact_snippets": "Any clinically important abnormalities (as assessed by the Investigator) in rhythm, conduction, or morphology of resting ECGs",
                        "criterion": "resting ECG",
                        "requirement": {
                            "requirement_type": "abnormality (rhythm)",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any clinically important abnormalities (as assessed by the Investigator) in rhythm, conduction, or morphology of resting ECGs",
                        "criterion": "resting ECG",
                        "requirement": {
                            "requirement_type": "abnormality (conduction)",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any clinically important abnormalities (as assessed by the Investigator) in rhythm, conduction, or morphology of resting ECGs",
                        "criterion": "resting ECG",
                        "requirement": {
                            "requirement_type": "abnormality (morphology)",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Any clinically important abnormalities (as assessed by the Investigator) in rhythm, conduction, or morphology of resting ECGs",
                        "criterion": "resting ECG",
                        "requirement": {
                            "requirement_type": "abnormality (rhythm)",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any clinically important abnormalities (as assessed by the Investigator) in rhythm, conduction, or morphology of resting ECGs",
                        "criterion": "resting ECG",
                        "requirement": {
                            "requirement_type": "abnormality (conduction)",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any clinically important abnormalities (as assessed by the Investigator) in rhythm, conduction, or morphology of resting ECGs",
                        "criterion": "resting ECG",
                        "requirement": {
                            "requirement_type": "abnormality (morphology)",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Prior radiotherapy within 2 weeks of enrolment or within 4 weeks of enrolment in the case of radiation to central nervous system (CNS), which requires ≥ 4-week washout. Patients must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.",
                "criterions": [
                    {
                        "exact_snippets": "Prior radiotherapy within 2 weeks of enrolment",
                        "criterion": "prior radiotherapy",
                        "requirement": {
                            "requirement_type": "time since prior radiotherapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "within 4 weeks of enrolment in the case of radiation to central nervous system (CNS)",
                        "criterion": "prior CNS radiotherapy",
                        "requirement": {
                            "requirement_type": "time since prior CNS radiotherapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Patients must have recovered from all radiation-related toxicities",
                        "criterion": "recovery from radiation-related toxicities",
                        "requirement": {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "not require corticosteroids",
                        "criterion": "corticosteroid requirement",
                        "requirement": {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "not have had radiation pneumonitis",
                        "criterion": "history of radiation pneumonitis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "or_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Prior radiotherapy within 2 weeks of enrolment",
                                        "criterion": "prior radiotherapy",
                                        "requirement": {
                                            "requirement_type": "time since prior radiotherapy",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 2,
                                                "unit": "weeks"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "within 4 weeks of enrolment in the case of radiation to central nervous system (CNS)",
                                        "criterion": "prior CNS radiotherapy",
                                        "requirement": {
                                            "requirement_type": "time since prior CNS radiotherapy",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 4,
                                                "unit": "weeks"
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "exact_snippets": "Patients must have recovered from all radiation-related toxicities",
                        "criterion": "recovery from radiation-related toxicities",
                        "requirement": {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "not require corticosteroids",
                        "criterion": "corticosteroid requirement",
                        "requirement": {
                            "requirement_type": "requirement",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "not have had radiation pneumonitis",
                        "criterion": "history of radiation pneumonitis",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Participation in any other study with an investigational study drug or device requires Medical Monitor approval.",
                "criterions": [
                    {
                        "exact_snippets": "Participation in any other study with an investigational study drug or device",
                        "criterion": "participation in other study with investigational drug or device",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Participation in any other study with an investigational study drug or device",
                        "criterion": "participation in other study with investigational drug or device",
                        "requirement": {
                            "requirement_type": "approval",
                            "expected_value": "Medical Monitor approval required"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Participation in any other study with an investigational study drug or device",
                                "criterion": "participation in other study with investigational drug or device",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "not_criteria": {
                                    "exact_snippets": "Participation in any other study with an investigational study drug or device",
                                    "criterion": "participation in other study with investigational drug or device",
                                    "requirement": {
                                        "requirement_type": "approval",
                                        "expected_value": "Medical Monitor approval required"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "2. Gastro-intestinal bowel obstruction (partial or complete).",
                "criterions": [
                    {
                        "exact_snippets": "Gastro-intestinal bowel obstruction (partial or complete)",
                        "criterion": "gastro-intestinal bowel obstruction",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Gastro-intestinal bowel obstruction (partial or complete)",
                        "criterion": "gastro-intestinal bowel obstruction",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "5. Presence of at least 1 measurable lesion by computed tomography or magnetic resonance imaging per RECIST v1.1 as determined by the local site investigator/radiologist assessment.",
                "criterions": [
                    {
                        "exact_snippets": "Presence of at least 1 measurable lesion by computed tomography or magnetic resonance imaging per RECIST v1.1",
                        "criterion": "measurable lesion",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Presence of at least 1 measurable lesion by computed tomography or magnetic resonance imaging per RECIST v1.1",
                        "criterion": "measurable lesion",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Presence of at least 1 measurable lesion by computed tomography or magnetic resonance imaging per RECIST v1.1",
                        "criterion": "measurable lesion",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Presence of at least 1 measurable lesion by computed tomography or magnetic resonance imaging per RECIST v1.1",
                        "criterion": "measurable lesion",
                        "requirement": {
                            "requirement_type": "assessment_method",
                            "expected_value": [
                                "computed tomography",
                                "magnetic resonance imaging"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Presence of at least 1 measurable lesion by computed tomography or magnetic resonance imaging per RECIST v1.1",
                        "criterion": "measurable lesion",
                        "requirement": {
                            "requirement_type": "criteria_version",
                            "expected_value": "RECIST v1.1"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "7. Willingness to undergo two fresh liver biopsies (pre-treatment and on-treatment).",
                "criterions": [
                    {
                        "exact_snippets": "Willingness to undergo two fresh liver biopsies (pre-treatment and on-treatment)",
                        "criterion": "willingness to undergo liver biopsies",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Willingness to undergo two fresh liver biopsies (pre-treatment and on-treatment)",
                        "criterion": "willingness to undergo liver biopsies",
                        "requirement": {
                            "requirement_type": "number of biopsies",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "biopsies"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Willingness to undergo two fresh liver biopsies (pre-treatment and on-treatment)",
                        "criterion": "willingness to undergo liver biopsies",
                        "requirement": {
                            "requirement_type": "type of biopsy",
                            "expected_value": "fresh liver biopsy"
                        }
                    },
                    {
                        "exact_snippets": "Willingness to undergo two fresh liver biopsies (pre-treatment and on-treatment)",
                        "criterion": "willingness to undergo liver biopsies",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": [
                                "pre-treatment",
                                "on-treatment"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "10. Has resolution of all toxicities and any toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia). Patients with ≤ Grade 2 neuropathy and Grade ≤ 2 fatigue are an exception and may enroll.",
                "criterions": [
                    {
                        "exact_snippets": "resolution of all toxicities and any toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia)",
                        "criterion": "toxicities and toxic effects of most recent prior therapy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE Grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Patients with ≤ Grade 2 neuropathy ... may enroll",
                        "criterion": "neuropathy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "CTCAE Grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Grade ≤ 2 fatigue ... may enroll",
                        "criterion": "fatigue",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "CTCAE Grade"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "and_criteria": [
                        {
                            "exact_snippets": "neuropathy",
                            "criterion": "neuropathy",
                            "requirement": {
                                "requirement_type": "severity",
                                "expected_value": {
                                    "operator": "<=",
                                    "value": 2,
                                    "unit": "CTCAE Grade"
                                }
                            }
                        },
                        {
                            "exact_snippets": "Grade \u00104 2 fatigue ... may enroll",
                            "criterion": "fatigue",
                            "requirement": {
                                "requirement_type": "severity",
                                "expected_value": {
                                    "operator": "<=",
                                    "value": 2,
                                    "unit": "CTCAE Grade"
                                }
                            }
                        }
                    ]
                },
                "then_criteria": null,
                "else_criteria": {
                    "and_criteria": [
                        {
                            "exact_snippets": "resolution of all toxicities and any toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia)",
                            "criterion": "toxicities and toxic effects of most recent prior therapy",
                            "requirement": {
                                "requirement_type": "severity",
                                "expected_value": {
                                    "operator": "<=",
                                    "value": 1,
                                    "unit": "CTCAE Grade"
                                }
                            }
                        }
                    ]
                }
            }
        },
        {
            "identified_line": {
                "line": "10. Resolution of all toxicities and any toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia). Patients with ≤ Grade 2 neuropathy and Grade ≤ 2 fatigue are an exception and may enroll.",
                "criterions": [
                    {
                        "exact_snippets": "Resolution of all toxicities and any toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia)",
                        "criterion": "toxicities and toxic effects of most recent prior therapy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "CTCAE grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Patients with ≤ Grade 2 neuropathy ... may enroll",
                        "criterion": "neuropathy",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "CTCAE grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Grade ≤ 2 fatigue ... may enroll",
                        "criterion": "fatigue",
                        "requirement": {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "CTCAE grade"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "and_criteria": [
                        {
                            "exact_snippets": "neuropathy ... may enroll",
                            "criterion": "neuropathy",
                            "requirement": {
                                "requirement_type": "severity",
                                "expected_value": {
                                    "operator": "<=",
                                    "value": 2,
                                    "unit": "CTCAE grade"
                                }
                            }
                        },
                        {
                            "exact_snippets": "Grade ≤ 2 fatigue ... may enroll",
                            "criterion": "fatigue",
                            "requirement": {
                                "requirement_type": "severity",
                                "expected_value": {
                                    "operator": "<=",
                                    "value": 2,
                                    "unit": "CTCAE grade"
                                }
                            }
                        }
                    ]
                },
                "then_criteria": null,
                "else_criteria": {
                    "exact_snippets": "Resolution of all toxicities and any toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia)",
                    "criterion": "toxicities and toxic effects of most recent prior therapy",
                    "requirement": {
                        "requirement_type": "severity",
                        "expected_value": {
                            "operator": "<=",
                            "value": 1,
                            "unit": "CTCAE grade"
                        }
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "4. Must have received a first line of SoC systemic therapy (physician choice) for stage IV disease and completed the therapy. They must have an ongoing partial response (PR) or a stable disease (SD) at the completion of this therapy, completion of therapy as defined by the investigator, however, with a minimum number of 4 months.",
                "criterions": [
                    {
                        "exact_snippets": "Must have received a first line of SoC systemic therapy (physician choice) for stage IV disease",
                        "criterion": "first line of SoC systemic therapy for stage IV disease",
                        "requirement": {
                            "requirement_type": "receipt",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "completed the therapy",
                        "criterion": "first line of SoC systemic therapy for stage IV disease",
                        "requirement": {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "They must have an ongoing partial response (PR) or a stable disease (SD) at the completion of this therapy",
                        "criterion": "disease status at completion of first line therapy",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": [
                                "partial response",
                                "stable disease"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "completion of therapy as defined by the investigator, however, with a minimum number of 4 months",
                        "criterion": "duration of first line therapy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "16. Measured or calculated creatinine clearance (glomerular filtration rate can also be used in place of creatinine clearance) ≥ 50 mL/min according to the formula of Cockcroft-Gault.",
                "criterions": [
                    {
                        "exact_snippets": "Measured or calculated creatinine clearance (glomerular filtration rate can also be used in place of creatinine clearance) ≥ 50 mL/min according to the formula of Cockcroft-Gault.",
                        "criterion": "renal function (creatinine clearance or glomerular filtration rate)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Measured or calculated creatinine clearance (glomerular filtration rate can also be used in place of creatinine clearance) ≥ 50 mL/min according to the formula of Cockcroft-Gault.",
                        "criterion": "renal function (creatinine clearance or glomerular filtration rate)",
                        "requirement": {
                            "requirement_type": "measurement_method",
                            "expected_value": [
                                "measured creatinine clearance",
                                "calculated creatinine clearance",
                                "glomerular filtration rate"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Measured or calculated creatinine clearance (glomerular filtration rate can also be used in place of creatinine clearance) ≥ 50 mL/min according to the formula of Cockcroft-Gault.",
                        "criterion": "renal function (creatinine clearance or glomerular filtration rate)",
                        "requirement": {
                            "requirement_type": "calculation_formula",
                            "expected_value": "Cockcroft-Gault"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "Specific to Cohorts 3, 4a, 4b:",
                "criterions": [
                    {
                        "exact_snippets": "Specific to Cohorts 3, 4a, 4b",
                        "criterion": "cohort assignment",
                        "requirement": {
                            "requirement_type": "cohort",
                            "expected_value": [
                                "3",
                                "4a",
                                "4b"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "5. Presence of at least 1 measurable lesion by computed tomography or magnetic resonance imaging per RECIST v1.1 as determined by the local site investigator/radiologist assessment.",
                "criterions": [
                    {
                        "exact_snippets": "Presence of at least 1 measurable lesion by computed tomography or magnetic resonance imaging per RECIST v1.1",
                        "criterion": "measurable lesion",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Presence of at least 1 measurable lesion by computed tomography or magnetic resonance imaging per RECIST v1.1",
                        "criterion": "measurable lesion",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Presence of at least 1 measurable lesion by computed tomography or magnetic resonance imaging per RECIST v1.1",
                        "criterion": "measurable lesion",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Presence of at least 1 measurable lesion by computed tomography or magnetic resonance imaging per RECIST v1.1",
                        "criterion": "measurable lesion",
                        "requirement": {
                            "requirement_type": "assessment_method",
                            "expected_value": [
                                "computed tomography",
                                "magnetic resonance imaging"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Presence of at least 1 measurable lesion by computed tomography or magnetic resonance imaging per RECIST v1.1",
                        "criterion": "measurable lesion",
                        "requirement": {
                            "requirement_type": "criteria_version",
                            "expected_value": "RECIST v1.1"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "15. Measured or calculated creatinine clearance (glomerular filtration rate can also be used in place of creatinine clearance) ≥ 50 mL/min according to the formula of Cockcroft-Gault (see Appendix 6).",
                "criterions": [
                    {
                        "exact_snippets": "Measured or calculated creatinine clearance ... ≥ 50 mL/min",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "glomerular filtration rate can also be used in place of creatinine clearance ... ≥ 50 mL/min",
                        "criterion": "glomerular filtration rate",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Measured or calculated creatinine clearance ... \u001e 50 mL/min",
                        "criterion": "creatinine clearance",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    },
                    {
                        "exact_snippets": "glomerular filtration rate can also be used in place of creatinine clearance ... \u001e 50 mL/min",
                        "criterion": "glomerular filtration rate",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "mL/min"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "7. Eligible for R0 complete liver metastasectomy (in case the primary tumor was already removed) or for R0 complete simultaneous combined resection (resection of both liver metastases and primary tumor in case the primary tumor is still in place) with curative intent.",
                "criterions": [
                    {
                        "exact_snippets": "Eligible for R0 complete liver metastasectomy (in case the primary tumor was already removed)",
                        "criterion": "eligibility for R0 complete liver metastasectomy",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Eligible for R0 complete liver metastasectomy (in case the primary tumor was already removed)",
                        "criterion": "eligibility for R0 complete liver metastasectomy",
                        "requirement": {
                            "requirement_type": "primary tumor status",
                            "expected_value": "already removed"
                        }
                    },
                    {
                        "exact_snippets": "Eligible for ... R0 complete simultaneous combined resection (resection of both liver metastases and primary tumor in case the primary tumor is still in place) with curative intent.",
                        "criterion": "eligibility for R0 complete simultaneous combined resection",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Eligible for ... R0 complete simultaneous combined resection (resection of both liver metastases and primary tumor in case the primary tumor is still in place) with curative intent.",
                        "criterion": "eligibility for R0 complete simultaneous combined resection",
                        "requirement": {
                            "requirement_type": "resection targets",
                            "expected_value": [
                                "liver metastases",
                                "primary tumor"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "Eligible for ... R0 complete simultaneous combined resection (resection of both liver metastases and primary tumor in case the primary tumor is still in place) with curative intent.",
                        "criterion": "eligibility for R0 complete simultaneous combined resection",
                        "requirement": {
                            "requirement_type": "primary tumor status",
                            "expected_value": "still in place"
                        }
                    },
                    {
                        "exact_snippets": "Eligible for ... R0 complete simultaneous combined resection (resection of both liver metastases and primary tumor in case the primary tumor is still in place) with curative intent.",
                        "criterion": "eligibility for R0 complete simultaneous combined resection",
                        "requirement": {
                            "requirement_type": "intent",
                            "expected_value": "curative"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "3. Patient with histologically or cytologically confirmed stage IV CRC who has failed standard therapies.",
                "criterions": [
                    {
                        "exact_snippets": "histologically or cytologically confirmed stage IV CRC",
                        "criterion": "colorectal cancer (CRC) diagnosis",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "histologically or cytologically confirmed stage IV CRC",
                        "criterion": "colorectal cancer (CRC) diagnosis",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": "IV"
                        }
                    },
                    {
                        "exact_snippets": "has failed standard therapies",
                        "criterion": "prior standard therapy",
                        "requirement": {
                            "requirement_type": "failure",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "Cohorts 2b and 4b:",
                "criterions": [
                    {
                        "exact_snippets": "Cohorts 2b and 4b",
                        "criterion": "cohort assignment",
                        "requirement": {
                            "requirement_type": "cohort",
                            "expected_value": [
                                "2b",
                                "4b"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "3. Histologically or cytologically confirmed CRC and MSS/MMR proficient status confirmed by polymerase chain reaction (PCR)/ immunohistochemistry or next generation sequencing (NGS) assay at local institution.",
                "criterions": [
                    {
                        "exact_snippets": "Histologically or cytologically confirmed CRC",
                        "criterion": "colorectal cancer (CRC) diagnosis",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histology",
                                "cytology"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "MSS/MMR proficient status confirmed by polymerase chain reaction (PCR)/ immunohistochemistry or next generation sequencing (NGS) assay",
                        "criterion": "MSS/MMR proficient status",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "proficient"
                        }
                    },
                    {
                        "exact_snippets": "MSS/MMR proficient status confirmed by polymerase chain reaction (PCR)/ immunohistochemistry or next generation sequencing (NGS) assay",
                        "criterion": "MSS/MMR proficient status",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "polymerase chain reaction (PCR)",
                                "immunohistochemistry",
                                "next generation sequencing (NGS) assay"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "Cohorts 1b, 2a, 2c, 3 and 4a:",
                "criterions": [
                    {
                        "exact_snippets": "Cohorts 1b, 2a, 2c, 3 and 4a",
                        "criterion": "cohort assignment",
                        "requirement": {
                            "requirement_type": "membership",
                            "expected_value": [
                                "1b",
                                "2a",
                                "2c",
                                "3",
                                "4a"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "17. Total bilirubin ≤ 1.5 × upper limit of normal (ULN); if total bilirubin is > 1.5 x ULN then direct bilirubin must be ≤ 1.5 × ULN. Patients with known Gilbert's Syndrome may enroll if total bilirubin ≤ 3 × ULN.",
                "criterions": [
                    {
                        "exact_snippets": "Total bilirubin ≤ 1.5 × upper limit of normal (ULN)",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "if total bilirubin is > 1.5 x ULN then direct bilirubin must be ≤ 1.5 × ULN",
                        "criterion": "direct bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Patients with known Gilbert's Syndrome may enroll if total bilirubin ≤ 3 × ULN",
                        "criterion": "total bilirubin in patients with known Gilbert's Syndrome",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "condition": {
                            "exact_snippets": "Patients with known Gilbert's Syndrome may enroll if total bilirubin \u001c 3 \u001d ULN",
                            "criterion": "total bilirubin in patients with known Gilbert's Syndrome",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": {
                                    "operator": "<=",
                                    "value": 3,
                                    "unit": "ULN"
                                }
                            }
                        },
                        "then_criteria": null,
                        "else_criteria": null
                    },
                    {
                        "condition": {
                            "exact_snippets": "Total bilirubin \u001c 1.5 \u001d upper limit of normal (ULN)",
                            "criterion": "total bilirubin",
                            "requirement": {
                                "requirement_type": "quantity",
                                "expected_value": {
                                    "operator": "<=",
                                    "value": 1.5,
                                    "unit": "ULN"
                                }
                            }
                        },
                        "then_criteria": null,
                        "else_criteria": {
                            "condition": {
                                "exact_snippets": "if total bilirubin is > 1.5 x ULN then direct bilirubin must be \u001c 1.5 \u001d ULN",
                                "criterion": "direct bilirubin",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "ULN"
                                    }
                                }
                            },
                            "then_criteria": null,
                            "else_criteria": null
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "3. Histologically or cytologically confirmed CRC and MSS/MMR proficient status confirmed by PCR/immunohistochemistry or NGS assay at local institution.",
                "criterions": [
                    {
                        "exact_snippets": "Histologically or cytologically confirmed CRC",
                        "criterion": "colorectal cancer (CRC) diagnosis",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "MSS/MMR proficient status confirmed by PCR/immunohistochemistry or NGS assay",
                        "criterion": "microsatellite status (MSS/MMR proficient)",
                        "requirement": {
                            "requirement_type": "status",
                            "expected_value": "MSS/MMR proficient"
                        }
                    },
                    {
                        "exact_snippets": "MSS/MMR proficient status confirmed by PCR/immunohistochemistry or NGS assay",
                        "criterion": "microsatellite status (MSS/MMR proficient)",
                        "requirement": {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "PCR",
                                "immunohistochemistry",
                                "NGS assay"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "4. Radiological evidence (CT/MRI) of liver-limited stage IV CRC.",
                "criterions": [
                    {
                        "exact_snippets": "Radiological evidence (CT/MRI)",
                        "criterion": "radiological evidence of disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Radiological evidence (CT/MRI)",
                        "criterion": "radiological evidence of disease",
                        "requirement": {
                            "requirement_type": "modality",
                            "expected_value": [
                                "CT",
                                "MRI"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "liver-limited stage IV CRC",
                        "criterion": "stage IV colorectal cancer",
                        "requirement": {
                            "requirement_type": "site of metastasis",
                            "expected_value": "liver-limited"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "4. Must have received Standard of Care systemic treatment consisting of fluoropyrimidin- oxaliplatin and/or irinotecan based therapy for stage IV CRC disease.",
                "criterions": [
                    {
                        "exact_snippets": "Must have received Standard of Care systemic treatment",
                        "criterion": "Standard of Care systemic treatment",
                        "requirement": {
                            "requirement_type": "receipt",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "fluoropyrimidin- oxaliplatin and/or irinotecan based therapy",
                        "criterion": "systemic therapy type",
                        "requirement": {
                            "requirement_type": "therapy_regimen",
                            "expected_value": [
                                "fluoropyrimidin-oxaliplatin",
                                "irinotecan"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "for stage IV CRC disease",
                        "criterion": "disease stage",
                        "requirement": {
                            "requirement_type": "stage",
                            "expected_value": "IV"
                        }
                    },
                    {
                        "exact_snippets": "for stage IV CRC disease",
                        "criterion": "disease stage",
                        "requirement": {
                            "requirement_type": "disease",
                            "expected_value": "colorectal cancer"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "12. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L.",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) ≥ 1.5 × 10^9/L.",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "10^9/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute neutrophil count (ANC) \u001e 1.5 \u0000d 10^9/L.",
                        "criterion": "absolute neutrophil count (ANC)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "10^9/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "13. Absolute lymphocyte count ≥ 0.5 × 109/L.",
                "criterions": [
                    {
                        "exact_snippets": "Absolute lymphocyte count ≥ 0.5 × 10^9/L.",
                        "criterion": "absolute lymphocyte count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "10^9/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute lymphocyte count \u001e 0.5 \u0000d 10^9/L.",
                        "criterion": "absolute lymphocyte count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "10^9/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "14. Platelets ≥ 100 × 109/L.",
                "criterions": [
                    {
                        "exact_snippets": "Platelets ≥ 100 × 10^9/L.",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "10^9/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelets \u00003e= 100 \u0000d7 10^9/L.",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "10^9/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "12. Absolute neutrophil count ≥ 1.5 × 109/L.",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count ≥ 1.5 × 10^9/L.",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "10^9/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute neutrophil count \u001e 1.5 \u0000d 10^9/L.",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "10^9/L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "11. Absolute neutrophil count ≥ 1.5 × 109 /L.",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count ≥ 1.5 × 10^9 /L.",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "× 10^9 /L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute neutrophil count \u001e 1.5 \u0000d 10^9 /L.",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "\u0000d 10^9 /L"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "13. Absolute lymphocyte count ≥ 0.5 × 109/L.",
                "criterions": [
                    {
                        "exact_snippets": "Absolute lymphocyte count ≥ 0.5 × 10^9/L.",
                        "criterion": "absolute lymphocyte count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "10^9/L"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute lymphocyte count  0.5 \u0000d 10^9/L.",
                        "criterion": "absolute lymphocyte count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.5,
                                "unit": "10^9/L"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "12. Pregnant/nursing women or unwilling to comply with acceptable contraceptive methods during study course.",
                "criterions": [
                    {
                        "exact_snippets": "Pregnant/nursing women",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "pregnant",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Pregnant/nursing women",
                        "criterion": "nursing status",
                        "requirement": {
                            "requirement_type": "nursing",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "unwilling to comply with acceptable contraceptive methods during study course",
                        "criterion": "willingness to comply with contraceptive methods",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "Pregnant/nursing women",
                                "criterion": "pregnancy status",
                                "requirement": {
                                    "requirement_type": "pregnant",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Pregnant/nursing women",
                                "criterion": "nursing status",
                                "requirement": {
                                    "requirement_type": "nursing",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "unwilling to comply with acceptable contraceptive methods during study course",
                        "criterion": "willingness to comply with contraceptive methods",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "6. Prior chemotherapy or targeted small molecule therapy within 15 days from initiation of study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Prior chemotherapy or targeted small molecule therapy within 15 days from initiation of study treatment.",
                        "criterion": "prior chemotherapy",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 15,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Prior chemotherapy or targeted small molecule therapy within 15 days from initiation of study treatment.",
                        "criterion": "prior targeted small molecule therapy",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 15,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Prior chemotherapy or targeted small molecule therapy within 15 days from initiation of study treatment.",
                        "criterion": "prior chemotherapy",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 15,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Prior chemotherapy or targeted small molecule therapy within 15 days from initiation of study treatment.",
                        "criterion": "prior targeted small molecule therapy",
                        "requirement": {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": "<=",
                                "value": 15,
                                "unit": "days"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "9. Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry with the exception of cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, ductal or lobular carcinoma in situ of the breast, or other non-invasive or indolent malignancy, or cancers from which the patient has been disease-free for > 1 year, after treatment with curative intent.",
                "criterions": [
                    {
                        "exact_snippets": "Known additional malignancy that is progressing or requires active treatment",
                        "criterion": "additional malignancy",
                        "requirement": {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Known additional malignancy that is progressing or requires active treatment",
                        "criterion": "additional malignancy",
                        "requirement": {
                            "requirement_type": "active treatment requirement",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "history of other malignancy within 2 years of study entry",
                        "criterion": "history of other malignancy",
                        "requirement": {
                            "requirement_type": "time since diagnosis",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "with the exception of cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, ductal or lobular carcinoma in situ of the breast, or other non-invasive or indolent malignancy",
                        "criterion": "type of prior malignancy",
                        "requirement": {
                            "requirement_type": "malignancy type",
                            "expected_value": [
                                "cured basal cell carcinoma of the skin",
                                "cured squamous cell carcinoma of the skin",
                                "superficial bladder cancer",
                                "prostate intraepithelial neoplasm",
                                "carcinoma in situ of the cervix",
                                "ductal carcinoma in situ of the breast",
                                "lobular carcinoma in situ of the breast",
                                "other non-invasive or indolent malignancy"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "cancers from which the patient has been disease-free for > 1 year, after treatment with curative intent",
                        "criterion": "disease-free interval after curative treatment for prior cancer",
                        "requirement": {
                            "requirement_type": "disease-free interval",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    },
                    {
                        "exact_snippets": "cancers from which the patient has been disease-free for > 1 year, after treatment with curative intent",
                        "criterion": "disease-free interval after curative treatment for prior cancer",
                        "requirement": {
                            "requirement_type": "treatment intent",
                            "expected_value": "curative"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "5. Prior therapy with checkpoint inhibitors (anti-programmed death 1 (anti-PD-1), anti-programmed death-ligand 1 (anti-PD-L1), anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4)). Patients must not have received any investigational immunotherapy neither.",
                "criterions": [
                    {
                        "exact_snippets": "Prior therapy with checkpoint inhibitors (anti-programmed death 1 (anti-PD-1), anti-programmed death-ligand 1 (anti-PD-L1), anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4))",
                        "criterion": "prior therapy with checkpoint inhibitors",
                        "requirement": {
                            "requirement_type": "history of therapy",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Patients must not have received any investigational immunotherapy",
                        "criterion": "prior investigational immunotherapy",
                        "requirement": {
                            "requirement_type": "history of therapy",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Prior therapy with checkpoint inhibitors (anti-programmed death 1 (anti-PD-1), anti-programmed death-ligand 1 (anti-PD-L1), anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4))",
                        "criterion": "prior therapy with checkpoint inhibitors",
                        "requirement": {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Patients must not have received any investigational immunotherapy",
                        "criterion": "prior investigational immunotherapy",
                        "requirement": {
                            "requirement_type": "history of therapy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "11. Previous vaccination (either therapeutic and/or prophylactic) against mCRC.",
                "criterions": [
                    {
                        "exact_snippets": "Previous vaccination (either therapeutic and/or prophylactic) against mCRC",
                        "criterion": "previous vaccination against mCRC",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Previous vaccination (either therapeutic and/or prophylactic) against mCRC",
                        "criterion": "previous vaccination against mCRC",
                        "requirement": {
                            "requirement_type": "type",
                            "expected_value": [
                                "therapeutic",
                                "prophylactic"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "20. Live vaccine received within 30 days before initiation of study treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed. however, intranasal influenza vaccines (FluMist®) are live attenuated vaccines and are not allowed. COVID-19 vaccines that are not live vaccines are allowed before and during study treatment. However, a COVID-19 vaccination should not occur within ± 2 days of ATP128 study drug and ± 15 days of VSV-GP128 study drug.",
                "criterions": [
                    {
                        "exact_snippets": "Live vaccine received within 30 days before initiation of study treatment",
                        "criterion": "live vaccine administration",
                        "requirement": {
                            "requirement_type": "time since administration before study treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed. however, intranasal influenza vaccines (FluMist®) are live attenuated vaccines and are not allowed.",
                        "criterion": "intranasal influenza vaccine (FluMist®) administration",
                        "requirement": {
                            "requirement_type": "administration",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "COVID-19 vaccines that are not live vaccines are allowed before and during study treatment. However, a COVID-19 vaccination should not occur within ± 2 days of ATP128 study drug and ± 15 days of VSV-GP128 study drug.",
                        "criterion": "COVID-19 vaccine administration",
                        "requirement": {
                            "requirement_type": "vaccine type",
                            "expected_value": "not live"
                        }
                    },
                    {
                        "exact_snippets": "COVID-19 vaccines that are not live vaccines are allowed before and during study treatment. However, a COVID-19 vaccination should not occur within ± 2 days of ATP128 study drug and ± 15 days of VSV-GP128 study drug.",
                        "criterion": "COVID-19 vaccine administration",
                        "requirement": {
                            "requirement_type": "timing relative to ATP128 study drug",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "COVID-19 vaccines that are not live vaccines are allowed before and during study treatment. However, a COVID-19 vaccination should not occur within ± 2 days of ATP128 study drug and ± 15 days of VSV-GP128 study drug.",
                        "criterion": "COVID-19 vaccine administration",
                        "requirement": {
                            "requirement_type": "timing relative to VSV-GP128 study drug",
                            "expected_value": {
                                "operator": ">=",
                                "value": 15,
                                "unit": "days"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "or_criteria": [
                            {
                                "exact_snippets": "Live vaccine received within 30 days before initiation of study treatment",
                                "criterion": "live vaccine administration",
                                "requirement": {
                                    "requirement_type": "time since administration before study treatment",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 30,
                                        "unit": "days"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "intranasal influenza vaccines (FluMist®) are live attenuated vaccines and are not allowed.",
                                "criterion": "intranasal influenza vaccine (FluMist®) administration",
                                "requirement": {
                                    "requirement_type": "administration",
                                    "expected_value": false
                                }
                            }
                        ]
                    },
                    {
                        "or_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "COVID-19 vaccines that are not live vaccines are allowed before and during study treatment.",
                                        "criterion": "COVID-19 vaccine administration",
                                        "requirement": {
                                            "requirement_type": "vaccine type",
                                            "expected_value": "not live"
                                        }
                                    },
                                    {
                                        "exact_snippets": "COVID-19 vaccination should not occur within ± 2 days of ATP128 study drug",
                                        "criterion": "COVID-19 vaccine administration",
                                        "requirement": {
                                            "requirement_type": "timing relative to ATP128 study drug",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 2,
                                                "unit": "days"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "COVID-19 vaccination should not occur within ± 15 days of VSV-GP128 study drug",
                                        "criterion": "COVID-19 vaccine administration",
                                        "requirement": {
                                            "requirement_type": "timing relative to VSV-GP128 study drug",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 15,
                                                "unit": "days"
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Ejection fraction (EF) < 55% or the lower limit of normal of the institutional standard will be excluded. Only in cases where the Investigator (or the treating physician or both) suspects cardiac disease with negative effect on the EF will the EF be measured during screening using an appropriate method according to local standards to confirm eligibility (e.g. echocardiogram [ECHO], multi-gated acquisition scan [MUGA]. A historic measurement of EF no older than 6 months prior to first study treatment administration can be accepted provided that there is clinical evidence that the EF value has not worsened since this measurement in the opinion of the Investigator or the treating physician or both.",
                "criterions": [
                    {
                        "exact_snippets": "Ejection fraction (EF) < 55% or the lower limit of normal of the institutional standard will be excluded.",
                        "criterion": "ejection fraction (EF)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 55,
                                        "unit": "%"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "Only in cases where the Investigator (or the treating physician or both) suspects cardiac disease with negative effect on the EF will the EF be measured during screening",
                        "criterion": "suspected cardiac disease with negative effect on EF",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "A historic measurement of EF no older than 6 months prior to first study treatment administration can be accepted provided that there is clinical evidence that the EF value has not worsened since this measurement in the opinion of the Investigator or the treating physician or both.",
                        "criterion": "historic EF measurement",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "A historic measurement of EF no older than 6 months prior to first study treatment administration can be accepted provided that there is clinical evidence that the EF value has not worsened since this measurement in the opinion of the Investigator or the treating physician or both.",
                        "criterion": "historic EF measurement",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "suspected cardiac disease with negative effect on EF will be measured during screening",
                                "criterion": "suspected cardiac disease with negative effect on EF",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Ejection fraction (EF) < 55% or the lower limit of normal of the institutional standard will be excluded.",
                                "criterion": "ejection fraction (EF)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 55,
                                                "unit": "%"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "historic EF measurement no older than 6 months prior to first study treatment administration can be accepted",
                                "criterion": "historic EF measurement",
                                "requirement": {
                                    "requirement_type": "recency",
                                    "expected_value": {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "clinical evidence that the EF value has not worsened since this measurement in the opinion of the Investigator or the treating physician or both.",
                                "criterion": "historic EF measurement",
                                "requirement": {
                                    "requirement_type": "stability",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Ejection fraction (EF) < 55% or the lower limit of normal of the institutional standard will be excluded.",
                                "criterion": "ejection fraction (EF)",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 55,
                                                "unit": "%"
                                            }
                                        ]
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Cohorts 1b, 2a, 2b, 2c, 3, 4a and 4b:",
                "criterions": [
                    {
                        "exact_snippets": "Cohorts 1b, 2a, 2b, 2c, 3, 4a and 4b",
                        "criterion": "cohort assignment",
                        "requirement": {
                            "requirement_type": "membership",
                            "expected_value": [
                                "1b",
                                "2a",
                                "2b",
                                "2c",
                                "3",
                                "4a",
                                "4b"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "13. History of autoimmune disease including any active autoimmune disease except vitiligo or childhood asthma.",
                "criterions": [
                    {
                        "exact_snippets": "History of autoimmune disease",
                        "criterion": "autoimmune disease",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any active autoimmune disease except vitiligo or childhood asthma",
                        "criterion": "active autoimmune disease",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "any active autoimmune disease except vitiligo or childhood asthma",
                        "criterion": "active autoimmune disease",
                        "requirement": {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "vitiligo",
                                "childhood asthma"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "15. Chronic or concurrent active infectious disease requiring systemic antibodies, antifungal, or antiviral treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Chronic or concurrent active infectious disease",
                        "criterion": "infectious disease",
                        "requirement": {
                            "requirement_type": "chronicity",
                            "expected_value": [
                                "chronic",
                                "concurrent active"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "requiring systemic antibodies, antifungal, or antiviral treatment",
                        "criterion": "infectious disease treatment",
                        "requirement": {
                            "requirement_type": "treatment_type",
                            "expected_value": [
                                "systemic antibodies",
                                "antifungal",
                                "antiviral"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        },
        {
            "identified_line": {
                "line": "Note: Testing must be performed to determine eligibility. - Hepatitis B virus DNA must be undetectable and HBsAg negative at screening visit.- Hepatitis C antibody testing is allowed for screening purposes in countries where HCV RNA is not part of standard of care. In these cases, HCV antibody positive patients will be excluded.- Patients who have had definitive treatment for HCV are permitted if HCV RNA is undetectable at screening visit.",
                "criterions": [
                    {
                        "exact_snippets": "Hepatitis B virus DNA must be undetectable",
                        "criterion": "Hepatitis B virus DNA",
                        "requirement": {
                            "requirement_type": "detectability",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "HBsAg negative at screening visit",
                        "criterion": "HBsAg",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "HCV antibody positive patients will be excluded",
                        "criterion": "HCV antibody",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "HCV RNA is undetectable at screening visit",
                        "criterion": "HCV RNA",
                        "requirement": {
                            "requirement_type": "detectability",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "or_criteria": [
                            {
                                "not_criteria": {
                                    "and_criteria": [
                                        {
                                            "exact_snippets": "Hepatitis B virus DNA must be undetectable",
                                            "criterion": "Hepatitis B virus DNA",
                                            "requirement": {
                                                "requirement_type": "detectability",
                                                "expected_value": false
                                            }
                                        },
                                        {
                                            "exact_snippets": "HBsAg negative at screening visit",
                                            "criterion": "HBsAg",
                                            "requirement": {
                                                "requirement_type": "presence",
                                                "expected_value": false
                                            }
                                        }
                                    ]
                                }
                            },
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "HCV antibody positive patients will be excluded",
                                        "criterion": "HCV antibody",
                                        "requirement": {
                                            "requirement_type": "presence",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "not_criteria": {
                                            "exact_snippets": "HCV RNA is undetectable at screening visit",
                                            "criterion": "HCV RNA",
                                            "requirement": {
                                                "requirement_type": "detectability",
                                                "expected_value": false
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "4. Prior monoclonal antibody within 4 weeks or 5 half-lives (whichever is shorter) before administration of study treatment with the exception of bevacizumab (Avastin®), cetuximab (Erbitux®) and panitumumab (Vectibix®) which may have been received within 15 days from initiation of study treatment. Supportive care (e.g. denosumab) may be used before and during study treatment.",
                "criterions": [
                    {
                        "exact_snippets": "Prior monoclonal antibody within 4 weeks or 5 half-lives (whichever is shorter) before administration of study treatment",
                        "criterion": "prior monoclonal antibody therapy",
                        "requirement": {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "with the exception of bevacizumab (Avastin®), cetuximab (Erbitux®) and panitumumab (Vectibix®) which may have been received within 15 days from initiation of study treatment",
                        "criterion": "prior bevacizumab, cetuximab, or panitumumab therapy",
                        "requirement": {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 15,
                                "unit": "days"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Supportive care (e.g. denosumab) may be used before and during study treatment",
                        "criterion": "supportive care (e.g. denosumab)",
                        "requirement": {
                            "requirement_type": "use before and during study treatment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Prior monoclonal antibody within 4 weeks or 5 half-lives (whichever is shorter) before administration of study treatment",
                                "criterion": "prior monoclonal antibody therapy",
                                "requirement": {
                                    "requirement_type": "time since last administration",
                                    "expected_value": {
                                        "comparisons": [
                                            {
                                                "operator": ">=",
                                                "value": 4,
                                                "unit": "weeks"
                                            },
                                            {
                                                "operator": ">=",
                                                "value": 5,
                                                "unit": "half-lives"
                                            }
                                        ]
                                    }
                                }
                            },
                            {
                                "not_criteria": {
                                    "exact_snippets": "with the exception of bevacizumab (Avastin®), cetuximab (Erbitux®) and panitumumab (Vectibix®) which may have been received within 15 days from initiation of study treatment",
                                    "criterion": "prior bevacizumab, cetuximab, or panitumumab therapy",
                                    "requirement": {
                                        "requirement_type": "time since last administration",
                                        "expected_value": {
                                            "operator": ">=",
                                            "value": 15,
                                            "unit": "days"
                                        }
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "not_criteria": {
                                    "exact_snippets": "Prior monoclonal antibody within 4 weeks or 5 half-lives (whichever is shorter) before administration of study treatment",
                                    "criterion": "prior monoclonal antibody therapy",
                                    "requirement": {
                                        "requirement_type": "time since last administration",
                                        "expected_value": {
                                            "comparisons": [
                                                {
                                                    "operator": ">=",
                                                    "value": 4,
                                                    "unit": "weeks"
                                                },
                                                {
                                                    "operator": ">=",
                                                    "value": 5,
                                                    "unit": "half-lives"
                                                }
                                            ]
                                        }
                                    }
                                }
                            },
                            {
                                "exact_snippets": "with the exception of bevacizumab (Avastin®), cetuximab (Erbitux®) and panitumumab (Vectibix®) which may have been received within 15 days from initiation of study treatment",
                                "criterion": "prior bevacizumab, cetuximab, or panitumumab therapy",
                                "requirement": {
                                    "requirement_type": "time since last administration",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 15,
                                        "unit": "days"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "failed_miscellaneous": []
}